lens-10q_20180630.htm

0001564590-18-021287.txt : 20180810 0001564590-18-021287.hdr.sgml : 20180810 20180810163136 ACCESSION NUMBER: 0001564590-18-021287 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 48 CONFORMED PERIOD OF REPORT: 20180630 FILED AS OF DATE: 20180810 DATE AS OF CHANGE: 20180810 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Presbia PLC CENTRAL INDEX KEY: 0001591096 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 000000000 STATE OF INCORPORATION: L2 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-36824 FILM NUMBER: 181009258 BUSINESS ADDRESS: STREET 1: SANDYFORD OFFICE CENTRE, SUITE 7 STREET 2: 17 CORRIG ROAD CITY: DUBLIN STATE: L2 ZIP: 00000 BUSINESS PHONE: 353-1-551-1487 MAIL ADDRESS: STREET 1: SANDYFORD OFFICE CENTRE, SUITE 7 STREET 2: 17 CORRIG ROAD CITY: DUBLIN STATE: L2 ZIP: 00000 FORMER COMPANY: FORMER CONFORMED NAME: Presbia Ireland, Ltd DATE OF NAME CHANGE: 20131105 10-Q 1 lens-10q_20180630.htm 10-Q lens-10q_20180630.htm

UNITED STATES

SECURITIES and EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2018

☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission file number: 001-36824

Presbia PLC

(Exact name of registrant as specified in its charter)

Ireland	98-1162329
(State or other jurisdiction of incorporation or organization)	(IRS Employer Identification No.)

Suite 7, Sandyford Office Centre, 17 Corrig Road, Sandyford, Dublin 18 Ireland (Address of principal executive offices)	(Zip Code)

+353 (1) 551 1487

(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). ☒ Yes ☐ No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company” and “emerging growth company” in 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☐	Smaller reporting company	☒
		Emerging growth company	☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

The number of outstanding shares of the Registrant’s ordinary shares as of August 10, 2018 was 17,157,160 shares, $0.001 par value per share.

PRESBIA PLC

TABLE OF CONTENTS

FORM 10-Q

FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2018

Item		Page

	PART I. FINANCIAL INFORMATION

Item 1.	Condensed Consolidated Financial Statements	4

	Condensed Consolidated Balance Sheets as of June 30, 2018 (unaudited) and December 31, 2017	4

	Condensed Consolidated Statements of Operations for the three and six months ended June 30, 2018 and 2017 (unaudited)	5

	Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2018 and 2017 (unaudited)	6

	Notes to Condensed Consolidated Financial Statements (unaudited)	7

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	15

Item 3.	Quantitative and Qualitative Disclosures about Market Risk	19

Item 4.	Controls and Procedures	20

	PART II. OTHER INFORMATION

Item 1.	Legal Proceedings	20

Item 1A.	Risk Factors	20

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	21

Item 3.	Defaults Upon Senior Securities	21

Item 4.	Mine Safety Disclosures	21

Item 5.	Other Information	21

Item 6.	Exhibits	22

	Signatures	23

Cautionary Note Regarding Forward-Looking Statements

This Quarterly Report on Form 10-Q contains forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, that involve substantial risks and uncertainties. In some cases, you can identify forward-looking statements by the words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “objective,” “ongoing,” “plan,” “predict,” “project,” “potential,” “should,” “will,” or “would,” and or the negative of these terms, or other comparable terminology intended to identify statements about the future. These statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements.

Although we believe that we have a reasonable basis for each forward-looking statement contained in this Quarterly Report on Form 10-Q, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain.

The forward-looking statements in this Quarterly Report on Form 10-Q include, among other things, statements about:

•

the timing, progress and results of our U.S staged pivotal clinical trial and our regulatory submissions;

•

our ability to advance our microlens and successfully complete our U.S. staged pivotal clinical trial;

•

our ability to obtain pre-market approvals;

•

the commercialization of our microlens outside the U.S.;

•

our ability to continue as a going concern;

•

our anticipated cash needs and our needs for additional financing;

•

the implementation of our business model, strategic plans for our business, products and technology;

•

the scope of protection we are able to establish and maintain for intellectual property rights covering our products and technology;

•

estimates of our expenses, future revenues, capital requirements and our needs for additional financing;

•

the timing or likelihood of regulatory filings and approvals;

•

our financial performance; and

•

developments relating to our competitors and our industry.

You should refer to “Part I, Item 1A. Risk Factors” of our Annual Report on Form 10-K for the year ended December 31, 2017, filed with the Securities and Exchange Commission (”SEC”) on March 30, 2018 for a discussion of important factors that may cause our actual results to differ materially from those expressed or implied by our forward-looking statements. As a result of these factors, we cannot assure you that the forward-looking statements in this Quarterly Report on Form 10-Q will prove to be accurate. You should understand that it is not possible to predict or identify all such factors. Consequently, you should not consider any such list to be a complete discussion of all potential risks or uncertainties that may substantially impact our business. Moreover, we operate in a competitive and rapidly changing environment. New factors emerge from time to time and it is not possible to predict the impact of all of these factors on our business, financial condition or results of operations.

Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame or at all. We undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

You should read this Quarterly Report on Form 10-Q and any documents that we reference in this report completely and with the understanding that our actual future results may be materially different from what we expect. We qualify all of our forward-looking statements by these cautionary statements.

PART I. FINANCIAL INFORMATION

ITEM 1.

FINANCIAL STATEMENTS

PRESBIA PLC

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands, except share data and par value amount)

	June 30, 2018			December 31, 2017
Assets	(unaudited)
Current assets
Cash	$	3,328		$	3,236
Accounts receivable		23			8
Inventory, net		71			127
Prepaid expenses and other current assets		305			108
Total current assets		3,727			3,479
Property and equipment, net		410			477
Intangible asset		1,411			1,479
Other assets		77			127
Total assets	$	5,625		$	5,562
Liabilities and shareholders’ equity
Current liabilities
Accounts payable	$	471		$	628
Due to related parties		35			23
Note payable, current portion		482			480
Other current liabilities		744			1,151
Total current liabilities		1,732			2,282
Deferred rent		98			107
Due to related parties, net of current portion		—			12
Other liabilities, net of current portion		25			30
Total liabilities		1,855			2,431
Commitments and contingencies (note 7)
Shareholders' equity
Preferred Shares
Series A Redeemable Preferred Shares; $0.001 par value, 50,000,000 shares authorized; 100 and 0 shares issued and outstanding at June 30, 2018 and December 31, 2017		—			—
USA Preferred Shares; $0.01 par value, 8,000 shares authorized; 4,900 and 0 shares issued and outstanding at June 30, 2018 and December 31, 2017		—			—
Ordinary Shares
$0.001 par value, 350,000,000 shares authorized; 17,157,160 and 17,121,857 shares issued and outstanding at June 30, 2018 and December 31, 2017		17			17
Deferred ordinary Shares
€1.00 (US$1.35) par value, 39,994 shares authorized, issued and outstanding at June 30, 2018 and December 31, 2017		54			54
Additional paid-in capital		96,266			91,362
Accumulated deficit		(92,567	)		(88,302	)
Total shareholders' equity		3,770			3,131
Total liabilities and shareholders’ equity	$	5,625		$	5,562

See accompanying notes to these consolidated financial statements.

PRESBIA PLC

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(in thousands, except per share amounts)

(Unaudited)

	Three-Months Ended June 30,						Six-Months Ended June 30,
	2018			2017			2018			2017
Revenues	$	3		$	-		$	7		$	5
Cost of goods sold		1			17			48			28
Gross profit (loss)		2			(17	)		(41	)		(23	)
Operating expenses:
Research and development		974			2,022			1,684			3,863
Sales and marketing		360			816			712			1,777
General and administrative		894			1,649			1,756			3,403
Total operating expenses		2,228			4,487			4,152			9,043
Operating loss		(2,226	)		(4,504	)		(4,193	)		(9,066	)
Other expense		(10	)		—			(10	)		—
Interest expense		(10	)		(4	)		(19	)		(18	)
Loss before income tax provision		(2,246	)		(4,508	)		(4,222	)		(9,084	)
Income tax provision		5			25			43			41
Net loss	$	(2,251	)	$	(4,533	)	$	(4,265	)	$	(9,125	)
Net loss per ordinary share-basic and diluted	$	(0.13	)	$	(0.27	)	$	(0.25	)	$	(0.58	)
Weighted average shares outstanding - basic and diluted		17,079,548			16,956,056			17,042,358			15,618,001

See accompanying notes to these consolidated financial statements.

PRESBIA PLC

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands)

(Unaudited)

	Six-Months Ended June 30,
	2018			2017
Cash flow from operating activities:
Net loss	$	(4,265	)	$	(9,125	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		126			171
Inventory provisions		45			29
Stock-based compensation		8			1,038
Loss on disposition of fixed assets		9			—
Imputed interest expense		21			40
Changes in operating assets and liabilities:
Accounts receivable		(15	)		(7	)
Inventory		11			24
Prepaid expenses and other current assets		(196	)		(100	)
Other assets		50			(2	)
Accounts payable and other current liabilities		(747	)		698
Income taxes payable		69			39
Deferred rent		(9	)		58
Due to related parties		12			10
Net cash used in operating activities		(4,881	)		(7,127	)
Cash flow from investing activities:
Purchases of intangible assets		(2	)		(87	)
Purchases of property and equipment		—			(7	)
Net cash used in investing activities		(2	)		(94	)
Cash flow from financing activities:
Proceeds from issuance of ordinary shares from rights offering, net of costs		—			10,485
Proceeds from issuance of preferred shares, net of costs		4,994			—
Net cash provided by financing activities		4,994			10,485
Net increase in cash		111			3,264
Effect of exchange rate on cash		(19	)		71
Cash balance at beginning of period		3,236			7,333
Cash balance at end of period	$	3,328		$	10,668

See accompanying notes to these consolidated financial statements.

PRESBIA PLC

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

(1) Basis of Presentation

Principles of Consolidation. The accompanying consolidated financial statements have been derived from the historical cost basis of the assets and liabilities, financial condition and cash flows of Presbia PLC and Presbia Ireland, Limited, both organized in Ireland, Presbia Investments, a wholly-owned subsidiary of Presbia PLC organized in the Cayman Islands, and Presbia Ireland, Limited’s subsidiaries, Presbia Deutchland GmbH, Presbia USA, Inc., and OPL, LLC. Presbia Deutchland GmbH is organized in Germany, and Presbia USA, Inc. and OPL, LLC are both entities organized in the United States, and include Presbia USA, Inc.’s subsidiaries, Visitome, Inc. and PresbiBio, LLC, both organized in the United States, and OPL, LLC’s direct and indirect subsidiaries, PIP Holdings, C.V and Presbia Cooperatief U.A., both organized in the Netherlands, and PresbiOptical LLC, organized in the United States (collectively, including Presbia PLC, the “Company”). The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). The Company’s fiscal year ends on December 31. The entities presented in the consolidated financial statements have been under common control during the periods presented. All intercompany accounts have been eliminated in consolidation.

Basis of Presentation. The accompanying unaudited consolidated financial statements as of June 30, 2018 and for the three and six months ended June 30, 2018 and 2017, respectively, have been prepared in accordance with United States generally accepted accounting principles (“U.S.GAAP”) for interim financial reporting, and with the instructions to Form 10-Q and Article 8 of Regulation S-X. The accompanying consolidated balance sheet at December 31, 2017 has been derived from the audited consolidated balance sheet at December 31, 2017, contained in the annual report on Form 10-K for the year ended December 31, 2017. These consolidated financial statements should be read in conjunction with the audited consolidated financial statements presented in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2017, filed with the Securities and Exchange Commission on March 30, 2018. In the opinion of management, the accompanying consolidated financial statements reflect all adjustments which are necessary for a fair presentation of the results of operations and cash flows for the periods presented. The results of operations for such interim periods are not necessarily indicative of results of operations to be expected for the full year.

References to amounts in the consolidated financial statement sections are in thousands, except per share data, unless otherwise specified.

Liquidity

At June 30, 2018, the Company has an accumulated deficit of $92.6 million and it expects to incur significant additional future operating losses. As it continues to incur losses, the Company’s transition to profitability will depend on the successful development, approval and commercialization of its microlens. The Company may never achieve profitability, and unless and until it does, it will need to continue to raise additional capital. Based on the Company’s current business plan, management believes that its cash and cash equivalents at June 30, 2018 will not be sufficient to meet its anticipated cash requirements during the twelve-month period subsequent to the issuance of the financial statements included in this Quarterly Report on Form 10-Q. These factors raise substantial doubt about the Company’s ability to continue as a going concern within one year from the date this Quarterly Report on Form 10-Q is filed with the U.S. Securities and Exchange Commission (SEC). The Company’s current commercialization strategy is targeted to countries where the Company can establish the market for its technology. This commercialization strategy will undergo continual prioritization and in the future the Company may adjust its commercialization efforts to preserve its existing cash or realize better results than anticipated which could have a positive impact on cash. The Company’s U.S. pivotal clinical trial and planned FDA approval is its highest priority. The Company must raise additional capital to fund its operations. It plans to raise additional capital through equity offerings, debt financings, collaborations and/or licensing arrangements. Additional funds may not be available when the Company needs them on terms that are acceptable to the Company, or at all. If adequate funds are not available on acceptable terms, the Company may be required to delay, reduce the scope of, or curtail, its operations. To the extent that the Company raises additional funds by issuing equity securities, its shareholders will experience dilution, and debt financing, if available, may involve restrictive covenants.

(2) Summary of Significant Accounting Policies

During the six months ended June 30, 2018 there have been no changes to the Company’s significant accounting policies as described in the Annual Report on Form 10-K for the fiscal year ended December 31, 2017, other than the adoption of the new revenue recognition standard noted below.

Revenue Recognition

Prior to 2018, we recognized revenue when there is persuasive evidence that an arrangement exists with our customers, selling prices are fixed or determinable, title or risk of loss has passed, and collection is reasonably assured. Revenue was recognized upon shipment and payments are either received in advance, or net 30 days for lenses or net 14 days for accessories. Distributor arrangements included certain perfunctory acceptance provisions and a one-year warranty, from the date of shipment, that products are free from defects in material workmanship. Under such provisions customers may reject shipments via written notifications ranging from 14-45 days or exchange defective product under warranty for the same non-defective product. We have not had any significant rejected shipments or warranty claims. We did not grant price concessions to our distributors.

In 2012, we changed our commercialization strategy from exclusively using distributors to also targeting refractive laser centers equipped with femtosecond lasers, except in countries that require the use of distributors or sales representatives. In December 2017, in light our re-ordering of operational priorities, we have focused our commercialization and clinical trial efforts outside of the U.S. in Germany and South Korea, including established ophthalmic clinics in those countries. We recognize revenue from laser centers and ophthalmic clinics based upon an analysis of the terms of each customer arrangement and upon determination that persuasive evidence of an arrangement exists, selling prices are fixed or determinable, title or risk of loss has passed, and collection is reasonably assured. Revenues from laser centers and ophthalmic clinics during the three and six months ended June 30, 2018 and 2017 were not material.

Effective January 1, 2018, the Company adopted the provisions of Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 606, Revenue from Contracts with Customers (“ASC 606”), using the modified retrospective transition method. Under this method, the Company recognizes revenue based on an analysis of the goods and services provided to our customers in the ordinary course. We analyze all commercial agreements to identify (i) contracts and arrangements with customers that meet the criteria for revenue recognition under the new standard (ii) identify all performance obligations under the contractual arrangement, such as the delivery of our Microlens to our customers and any other deliverable(s) as defined in a commercial arrangement (iii) the determination of the transaction price and the allocation of such pricing over the defined contractual obligations in the contract with the customer and (iv) the recognition of revenue once the customer has assumed control over the contractual obligations. Control refers to the ability on the part of the customer to obtain substantially all the benefits of possession of the delivered product or service.

Foreign Currency

The functional currency of subsidiaries outside the United States of America is the U.S. Dollar. Transactions in foreign currencies during the year are re-measured at rates of exchange on the dates of the transactions. Gains and losses related to re-measurement of items arising through operating activities are accounted for in the statement of operations and comprehensive loss and included in general and administrative expense. Aggregate foreign exchange gains and losses are included in the Condensed Consolidated Statement of Operations. Aggregate foreign exchange gain was $28,000 for the three months ended June 30, 2018, and aggregate foreign exchange loss was $24,000 for the six months ended June 30, 2018. Aggregate foreign exchange loss was $52,000 and $79,000 for the three and six months ended June 30, 2017, respectively.

Comprehensive Loss

Comprehensive income or loss is defined as a change in equity of a company attributable to all transactions excluding those transactions resulting from investment with owners and distributions to owners. There were no differences between net loss and comprehensive loss in the three and six months ended June 30, 2018 and 2017.

Future Accounting Pronouncements

In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). The new standard requires lessees to recognize most leases on their balance sheets as lease liabilities with corresponding right-of-use assets and eliminates certain real estate-specific provisions. ASU 2016-02 will be effective for the Company in the first quarter of 2019. ASU 2016-02 will be adopted on a modified retrospective transition basis for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements. Although the Company is currently evaluating the full impact of ASU 2016-02 on its consolidated financial statements, upon adoption of ASU 2016-02 the Company anticipates that its operating leases will be recognized on the balance sheet as a lease liability if certain criteria is met, with a corresponding right of use asset.

In February 2018, the FASB issued ASU 2018-02, Income Statement—Reporting Comprehensive Income (Topic 220)—Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income. This update was issued to address the income tax accounting treatment of the stranded tax effects within other comprehensive income due to the prohibition of backward tracing due to an income tax rate change that was initially recorded in other comprehensive income. This issue came about from the enactment of the Tax Cuts and Jobs Act on December 22, 2017, which changed the Company’s income tax rate from 35% to 21%. The ASU changed current accounting whereby an entity may elect to reclassify the stranded tax effect from accumulated other comprehensive income to retained earnings. The ASU is effective for periods beginning after December 15, 2018, although early adoption is permitted. The Company does not anticipate that the adoption of this ASU will have a material impact on its consolidated financial statements.

In June 2018, the FASB issued ASU No. 2018-07, Compensation — Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting. The new standard expands the scope of Topic 718 to include all share-based payment transactions for acquiring goods and services from nonemployees. ASU No. 2018-07 specifies that Topic 718 applies to all share-based payment transactions in which the grantor acquires goods and services to be used or consumed in its own operations by issuing share-based payment awards. ASU NO. 2018-07 also clarifies that Topic 718 does not apply to share-based payments used to effectively provide (1) financing to the issuer or (2) awards granted in conjunction with selling goods or services to customers as part of a contract accounted for under ASC 606. ASU No. 2018-07 will be effective for the Company beginning after December 15, 2019, with early adoption permitted, but no earlier than the Company’s adoption of ASC 606. The Company is currently assessing the potential impact of adopting this guidance on its consolidated financial statements.

Recent Accounting Standards

In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606). The new standard is based on the principle that revenue should be recognized to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. ASU 2014-09 became effective for the Company in the first quarter of 2018 and allowed for full retrospective or a modified retrospective adoption approach. The Company adopted this new standard in January 2018 and it did not have a material adjustment on its consolidated financial statements.

In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows, which clarifies the classification of certain cash receipts and payments. The specific cash flow issues addressed by ASU 2016-15, with the objective of reducing the existing diversity in practice, are as follows: (1) Debt prepayment or debt extinguishment costs; (2) Settlement of zero-coupon debt instruments or other debt instruments with insignificant coupon interest rates; (3) Contingent consideration payments made after a business combination; (4) Proceeds from the settlement of insurance claims; (5) Proceeds from the settlement of corporate-owned life insurance policies; (6) Distributions received from equity method investees; (7) Beneficial interest in securitization transactions; and (8) Separately identifiable cash flows and application of the predominance in principle. ASU 2016-15 became effective for fiscal years beginning after December 15, 2017. The Company adopted this new standard in January 2018 and it did not have a material impact on its consolidated financial statements.

In October 2016, the FASB issued ASU. 2016-16, Income Taxes (Topic 740): Intra-Entity Transfers of Assets Other than Inventory. This update requires entities to recognize the income tax consequences of an intra-entity transfer of an asset other than inventory when the transfer occurs. This update is effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. Early adoption is permitted as of the beginning of a fiscal year. The new standard must be adopted using a modified retrospective transition method, which is a cumulative-effective adjustment to retained earnings as of the beginning of the first effective reporting period. The Company adopted this new standard in January 2018 and it did not have a material impact on its consolidated financial statements.

In May 2017, the FASB issued ASU 2017-09, Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting, which provides guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. This update is effective for annual reporting periods beginning after December 15, 2017. Early adoption is permitted. The Company adopted this ASU in January 2018 and it did not have a material impact on its consolidated financial statements.

(3) Loss per Share

Ordinary Shares and dilutive potential Ordinary Shares outstanding during the period. Dilutive potential ordinary shares consist of the shares issuable upon the exercise of options and upon the vesting of restricted shares under the treasury stock method. In net loss periods, basic and diluted net loss per share are identical since the effect of potential ordinary shares is anti-dilutive and therefore excluded.

Basic and diluted loss per share for the three and six months ended June 30, 2018 and 2017 were calculated as follows:

	Three-Months Ended June 30,						Six-Months Ended June 30,
	2018			2017			2018			2017
Net Loss	$	(2,251	)	$	(4,533	)	$	(4,265	)	$	(9,125	)
Weighted average shares outstanding - basic and diluted		17,079,548			16,956,056			17,042,358			15,618,001
Net loss per ordinary share - basic and diluted	$	(0.13	)	$	(0.27	)	$	(0.25	)	$	(0.58	)

Antidilutive securities, which consist of options and unvested restricted shares that are not included in the diluted net loss per share calculation, consisted of an aggregate of 1,049,795 and 1,152,500 weighted average shares for the three months ended June 30, 2018 and 2017, respectively and 972,019 and 1,050,000 for the six months ended June 30, 2018 and 2017, respectively.

(4) Equity Based Awards

Equity Issued by Presbia PLC

Presbia Incentive Plan

On January 14, 2015, the Company approved a compensation incentive plan (the “Presbia Incentive Plan”). The Presbia Incentive Plan permits the Company to grant awards of options, restricted shares, share appreciation rights, restricted share units, performance shares, performance share units, dividend equivalent rights in respect of awards and other share-based and cash-based awards, including annual and long-term cash incentive awards. A total of 2,200,000 ordinary shares are authorized for issuance under the Presbia Incentive Plan of which approximately 367,591 were available on June 30, 2018 for future grants and awards. The exercise price of each option award shall be determined by the Board of Directors (or a committee thereof) at the date of grant in accordance with the terms of the 2005 Plan, and under the Presbia Incentive Plan awards generally vest 20% annually over a five-year period and expire no later than 10 years from the grant date. The Presbia Incentive Plan terminates on January 14, 2025, unless terminated earlier by the board of directors. Awards under the Presbia Incentive Plan may be granted to employees, directors, consultants and other persons who perform services for the Company or a subsidiary of the Company.

The following table shows share-based compensation expense based upon all equity awards issued by Presbia PLC included in the Consolidated Statements of Operations for the three and six months ended June 30, 2018 and 2017. The Company recorded a credit of $86,000 and $524,000 as a result of the reversal of stock-based compensation for participants whose relationship with the Company terminated in the three and six months ended June 30, 2018, respectively.

	Three-Months Ended June 30,					Six-Months Ended June 30,
	2018			2017		2018			2017
Research and development	$	(49	)	$	126	$	(227	)	$	242
General and administrative		174			311		175			641
Sales and marketing		30			78		60			155
	$	155		$	515	$	8		$	1,038

Options

The following table sets forth the Company’s option activity for the six months ended June 30, 2018:

	Number of Presbia PLC Shares			Weighted Average Exercise Price Per Share		Aggregate Intrinsic Value
Balance, January 1, 2018		849,100		$	9.77		—
Granted		365,000		$	2.38		—
Exercised		—			—		—
Forfeited/cancelled/expired		(71,450	)	$	9.38		—
Balance, June 30, 2018		1,142,650		$	7.44		—
Vested, June 30, 2018		726,150		$	9.82		—
Non Vested, June 30, 2018		416,500		$	3.27		—
Exercisable, June 30, 2018		726,150		$	9.82		—

Employee Options

The Company utilizes the Black-Scholes valuation model for estimating the fair value of granted stock options with the following assumptions in addition to the closing price of the Company’s ordinary shares on the date of the grant: (i) the Company estimates the expected term of the option utilizing the simplified method because of its limited history of option exercise activity and its options meet the criteria of a "plain-vanilla" option as defined by the Securities Exchange Commission (ii) due to its limited stock price volatility history, the Company uses a peer group average as permitted under Accounting Standards Codification (“ASC”) 718 consistent with the expected term of the stock option at the time of the grant and (iii) applies a risk-free interest rate based on the U.S. Treasury securities yield consistent with the expected term of the option at the time of the grant. The simplified method calculates the expected term as the average of the weighted average vesting period and contractual terms of the award.

For those options granted to employees, stock-based compensation expense was based upon the fair value of the option as of the grant-date and attributed to future reporting periods on a straight-line basis over the vesting period, or the requisite service period. The Company adopted ASU 2016-09 on January 01, 2018, electing to account for forfeitures when they occur. The Company issued 365,000 and 0 employee options during the three and six months ended June 30, 2018. Options granted in 2018 vest 20% annually over a five-year period and expire 6.75 years from the grant date. The Company did not issue employee options during the three and six months ended June 30, 2017.

Non-Employee Options

During the three and six months ended June 30, 2018 and 2017, the Company did not grant options to non-employee consultants and medical advisors. In contrast to the determination of the fair value of options granted to employees, which are determined based upon the grant-date assumptions and applying the Black-Scholes model, the fair values for non-employee options and the related stock-based compensation expense are remeasured each financial reporting period based upon the assumptions applicable on the dates in which the financial statements are prepared, which are disclosed in the following table:

	Three-Months Ended June 30,				Six-Months Ended June 30,
	2018		2017			2018		2017
Stock price per share	$0.85 - $1.13		$1.25 - $1.63			$0.85 - $1.95		$1.25 - $2.51
Expected term	6.6 - 7.1 Yrs.		7.7 - 8.4 Yrs			6.6 - 7.4 Yrs.		7.7 - 8.6 Yrs
Volatility	72.9% - 77.3%		79.1% - 83.5%			72.9% - 77.3%		79.1% - 90.0%
Dividends		—		—			—		—
Risk-free rate	2.8%		2.2%			2.6% - 2.8%		2.2% - 2.3%

Because the performance criteria of these grants is based solely upon a requisite service period, but are subject to forfeiture if the service conditions are not met, stock-based compensation expense is determined by a straight-line attribution of the remeasured expense (mark-to-market) over the requisite service period subject to an adjustment to previously recognized expense in the event forfeitures occur.

Restricted Shares

The Company awarded 23,255 ordinary shares to the head of the Company’s medical advisory board as compensation for services provided during the six-month period ended June 30, 2018. The number of shares was determined by the closing price of $2.15 on June 29, 2018.

The following table sets forth the Company’s restricted share activity for the three and six months ended June 30, 2018:

	Unvested Number of Shares			Weighted Average Fair Value per Share
Balance, December 31, 2017		134,367		$	3.78
Granted		23,255			2.15
Vested		(104,731	)		3.02
Forfeited/cancelled		—			—
Unvested, June 30, 2018		52,891		$	5.45

Restricted Share Units

During the three and six months ended June 30, 2018, the Board of Directors did not award restricted share units (“RSU” or “RSU’s” or “RSU Plan”) to officers and employees in accordance with the guidelines provided by the Presbia Incentive Plan, which includes a provision that the recipient must be employed as a condition of vesting. The Presbia RSU Plan authorizes the issuance of 20% of each recipient’s total RSU award for the first occurrence that the closing price of the Company’s ordinary shares exceed, for a period of 20 consecutive business days, price thresholds of $10.00, $15.00, $20.00, $25.00 and $30.00, respectively. The RSU Plan also provides for a one-year “wait” or service period prior to any vesting permitted under the plan. The RSU Plan has a seven-year expiration period following the date of the grant.

Fair value of the RSU’s awarded are determined using a Monte Carlo Simulation (“MCS”) methodology, which considers the separate probabilities that each of the price thresholds or market conditions will be achieved under the RSU Plan guidelines. Each probability is weighted by its respective price threshold, or its intrinsic value, which provides the basis for an aggregate fair value. The Company used the following key inputs in determining the fair value using the MCS model: (i) the volatility of the entity’s common stock and (ii) the closing price of the entity’s stock as of the measurement date of the RSU award. In accordance with GAAP, the Company recognizes as stock-based compensation expense, using a straight-line attribution method, the aggregate fair value over future periods based upon the respective derived service periods and fair values for each of the price thresholds as provided by the MCS model.

The following table sets forth the Company’s RSU activity for the six months ended June 30, 2018:

	Unvested Number of Shares			Weighted Average Fair Value per Share
Balance, December 31, 2017		739,000		$	2.09
Granted		—			—
Vested		—			—
Forfeited/cancelled		(226,000	)		2.44
Unvested, June 30, 2018		513,000		$	1.32

Unrecognized Share-based Compensation

As of June 30, 2018 and 2017, there were $785,000 and $2,740,000, respectively, of unrecognized compensation expense related to employee and non-employee options of the Company, which collectively is expected to be recognized by the Company over the weighted average vesting period of 2.3 and 1.7 years, respectively. Unrecognized compensation expense for the same periods related to restricted shares was $226,000 and $290,000, respectively, and is expected to be recognized over the weighted average vesting periods of 1.8 and 1.5 years, respectively. As of June 30, 2018 and 2017, there was approximately $513,000 and 7,710,000 of unrecognized compensation expense with respect to the RSU’s over a weighted average remaining derived service period of 0.9 and 2.4 years, respectively.

(5) Concentration of Credit Risk

The Company had cash of $3.3 million and $3.2 million as of June 30, 2018 and December 31, 2017, respectively, which consists of checking account deposits. The Company maintains cash balances at financial institutions located in the United States and secured by the Federal Deposit Insurance Corporation up to $250,000.

As of June 30, 2018, the Company was not authorized to manufacture or sell any of its products or services within the United States and, as a result, all of the Company’ revenues are derived from foreign customers.

With respect to suppliers for the microlens, the Company had a five-year supplier agreement that expired in January 2017 with a lens manufacturer in Israel from which the Company received 100% of its lens supply for use in commercial activities outside the United States. The Company also has its own manufacturing facility in Irvine, California that the Company believes will be sufficient to supply lenses for commercial activities outside the United States once existing inventory is utilized, as well as in the United States, pending FDA approval.

(6) Income Taxes

Deferred income tax assets and liabilities are recognized for temporary differences between financial statement and income tax carrying values, using tax rates in effect for the years such differences are expected to reverse. Due to uncertainties surrounding the Company's ability to generate future taxable income and consequently realize such deferred income tax assets, a full valuation allowance has been established. The Company continues to maintain a full valuation allowance against its deferred tax assets as of June 30, 2018.

The impact of an uncertain income tax position on the income tax return must be recognized at the largest amount that is more likely than not to be sustained upon audit by the relevant tax authority. An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained. In December 2017, the Company recorded a liability of $199,000 with respect to unpaid Irish income taxes in accordance with ASC 740-10, , Accounting for Uncertainty of Income Taxes, and increased that liability during the six months ended June 30, 2018 to $274,000. The Company’s policy is to recognize interest expense and penalties related to income tax matters as a component of the income tax provision. As of June 30, 2018 and December 31, 2017, the Company had $35,000 and $39,000, respectively, of tax related accrued interest and penalties on its consolidated balance sheet or on its consolidated statement of operations.

A reconciliation of gross unrecognized tax benefits is as follows:



		June 30, 2018		December 31, 2017
Balance at the beginning of the year		199,000		—
Increases related to current year tax positions		75,000		199,000
Balance at the end of the year	$	274,000	$	199,000

(7) Equity Transaction with Related Party

Private Placement with Related Party

On April 12, 2018, Presbia PLC, its wholly-owned subsidiary, Presbia USA, Inc. and Richard Ressler, a member of Presbia PLC’s board of directors and its majority stockholder, entered into a Stock Purchase Agreement pursuant to which Mr. Ressler purchased in a private placement offering 100 preferred shares of the Company, with the rights set forth in the Subscription Letter, dated April 12, 2018, and 4,900 shares of preferred stock of Presbia USA for an aggregate purchase price of $5.0 million. Upon closing the offering, Mr. Ressler received a warrant to purchase 1,953,125 ordinary shares of Presbia PLC at an exercise price of $2.56 per share, subject to adjustments as provided under the terms of the warrants. The warrant is exercisable for five years from the issuance date and it contains a cashless exercise provision.

The preferred shares of Presbia PLC and Presbia USA carry a one times liquidation preference. The preferred shares are redeemable upon a liquidation event in which all classes of equity holders are entitled to receive the same form of consideration and are redeemable at any time at our sole election, provided that a majority of the independent directors approve such redemption. The preferred shares accrue a dividend at the rate of 10% per annum during the first 18 months, 20% for months 19 through 24 and 30% from month 25 until such preferred shares are redeemed, payable in preferred shares on a quarterly basis. Undeclared dividends for the period from the date of issuance of April 12, 2018 to June 30, 2018 is 50,334 preferred shares of the Company.

As long as the preferred shares remain outstanding, neither the Company nor its subsidiary shall take the following actions, without obtaining the prior consent of the holder of the preferred shares: (a) effect any alteration, repeal, change or amendment of the rights, privileges or preferences of the preferred shares in a manner that adversely affects the rights, privileges or preferences of those shares or any series thereof; (b) amend, modify or repeal any provision of the organizational documents in a manner that adversely affects the powers, preferences or rights of the preferred shares; (c) agree to any debt financing in an amount in excess of $8,000,000 (such amount being the maximum amount payable by the company under the debt instruments); (d) execute a guarantee; (e) effect any restructuring or liquidation; (f) settle any lawsuit or civil investigation requiring the payment of more than $1,000,000; or (g) execute any document or enter into any arrangement that has a potential liability to the Company in excess of $1,000,000.

In addition, Presbia PLC guaranteed Presbia USA’s payment of the redemption price and any accrued and unpaid dividends with respect to the preferred shares issued by Presbia USA.

(8) Commitments and Contingencies

In May 2012, the Company entered into a five-year non-cancelable lease for office and manufacturing space in Irvine, California that was renewed on June 1, 2016 and provided for an extension of five consecutive years starting from the original lease expiration date of May 31, 2017 through May 31, 2022. The Company maintains a one-year lease (which is now month to month) in Dublin, Ireland that commenced on December 1, 2013. In February 2018, it terminated a 30-month lease in Amsterdam, the Netherlands, that commenced on January 1, 2016. This termination was based on a mutual agreement with the landlord. In December 2017, the Company vacated one of its Irvine, California locations and consolidated its operations into another location in Irvine. At December 31, 2017, a liability of $222,000, representing the fair value of the remaining lease obligation over the remaining 33 months was recorded as part of the short-term portion of deferred rent in the Consolidated Balance Sheet. During the six-month period ended June 30, 2018, the Company sublet the facility and settled the remaining lease obligation. Aggregate rent expense for the three months ended June 30, 2018 and 2017 was $113,000 and $168,000, respectively, and for the six months ended for the same period was $208,000 and $337,000, respectively.

From time to time, the Company may be subject to legal proceedings and claims arising in the ordinary course of business. Management does not believe that the outcome of any of these matters will have a material effect on the Company’s consolidated financial operations.

(9) Subsequent Event

None

ITEM 2.

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

Unless we state otherwise, the terms “we,” “us,” “our,” “Presbia” and the “Company” refer to Presbia PLC and its consolidated subsidiaries after giving effect to the Reorganization Transactions. Prior to the completion of the Reorganization Transactions, the foregoing terms refer to the entities that became the consolidated subsidiaries of Presbia PLC upon consummation of the Reorganization Transactions.

Our Management’s Discussion and Analysis of Financial Condition and Results of Operations is organized as follows:

•

Overview. This section provides a general description of our Company and background information on certain trends and developments affecting our Company.

•

Critical Accounting Policies and Estimates. This section discusses those accounting policies that are considered important to the evaluation and reporting of our financial condition and results of operations, and whose application requires us to exercise subjective or complex judgments in making estimates and assumptions.

•

Overview of Results of Operations. This section provides our analysis and outlook for the significant line items on our consolidated statements of operations and comprehensive loss, as well as other information that we deem meaningful to understand our results of operations on a consolidated basis.

•

Liquidity and Capital Resources. This section provides an analysis of our liquidity and cash flows.

Overview

We are an ophthalmic device company which has developed and is currently marketing a proprietary optical lens implant for treating presbyopia, the age-related loss of the ability to focus on near objects. Our microlens is a miniature lens designed to be surgically implanted in a patient’s eye to improve that patient’s ability to see objects at close distances. Our current strategy is to focus on obtaining regulatory approval for our microlens in the United States and to continue to commercialize our microlens in certain strategic countries where we currently have marketing approval. Our goal is to become a leading provider of corneal inlay presbyopia-correcting treatment worldwide.

Although reading glasses and contact lenses have historically been, and remain, the most common solution for presbyopia, there are significant drawbacks associated with these approaches, as well as with alternative surgical approaches. We believe that our microlens provides an alternative solution to those presbyopic individuals who desire greater freedom from glasses and wish to avoid the daily maintenance and other complications of contact lenses. We believe that our microlens can be both an effective standalone solution for presbyopia and an effective complementary solution that can be used in conjunction with certain other surgical approaches that are used to treat vision disorders other than presbyopia.

Through our European Union CE Mark, we are generally authorized to market our microlens throughout the European Economic Area (all European Union member states plus Iceland, Liechtenstein and Norway), or “EEA”, and through mutual recognition agreements, in Switzerland. We currently market our microlens in certain strategic EEA countries as well as certain strategic countries outside of the EEA in which we possess marketing approval, such as South Korea. We obtained a five-year extension of our CE Mark in July, 2018.

We are focused on seeking marketing approval in the United States. In December 2013, we received approval to commence a staged pivotal clinical trial as part of the U.S. Food and Drug Administration, or “FDA”, approval process. Beginning in May 2014, we enrolled a total of 75 subjects at six investigational sites in the United States and each subject underwent insertion of our microlens in the non-dominant eye. Based on nine-month data on 52 subjects, in January 2015, we submitted an interim safety report as a supplement to our investigational device exemption, or “IDE”, to the FDA. In February 2015, we received approval from the FDA to commence second stage enrollment in this trial. During September 2015, we completed the enrollment of the second stage study of 346 subjects at up to five additional investigational sites. This trial is necessary in order to obtain clinical data to provide the primary support for a safety and effectiveness evaluation to support a pre-market approval, or “PMA”, for marketing clearance in the United States. Data on a minimum of 300 subjects with 24-month data will be submitted as part of the PMA, and all subjects will be followed for three years following implantation. We are pursuing a modular PMA submission strategy whereby we submitted to the FDA information regarding biocompatibility in the second quarter of 2016. We submitted to the FDA the second and third PMA modules in the first quarter of 2017, which contains information regarding preclinical testing, engineering and manufacturing. We submitted of our final PMA module, containing 24-month data on 300 subjects, to the FDA in the

second quarter of 2018. We are targeting PMA approval of our microlens in the fourth quarter of 2018. We are also targeting submission to the FDA of a final report with 36-month data on these 300 subjects in the first quarter of 2019.

These milestones could be delayed by further interactions with the FDA or by a variety of other factors. In addition, no assurance can be given that the FDA will grant us PMA approval or, if granted, that it will be granted in accordance with our anticipated time schedule. Also, the FDA may require us to conduct post-approval studies as a condition of approval.

We are a development stage ophthalmic device company with a limited operating history. We are not profitable and have incurred losses in each year since our formation. We have reported recurring net losses and negative cash flow from operating activities since inception and, as of June 30, 2018, we had an accumulated deficit of $92.6 million. We expect to continue to incur significant losses for the foreseeable future.

Critical Accounting Policies and Estimates

The discussion and analysis of our consolidated financial statements and results of operations is based upon our consolidated financial statements, which have been prepared in accordance with GAAP. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, costs and expenses and related disclosures. We have based and will base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances. In many instances, we could have reasonably used different accounting estimates, and in other instances changes in the accounting estimates are reasonably likely to occur from period to period. Accordingly, actual results could differ significantly from the estimates made by our management. To the extent that there are material differences between these estimates and actual results, our future financial statement presentation, financial condition, results of operations and cash flows will be affected. We believe that the accounting policies discussed below are critical to understanding our historical and future performance, as these policies relate to the more significant areas involving management’s judgments and estimates.

We describe our significant accounting policies in Note 2, “Summary of Significant Accounting Policies,” of our notes to consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2017. We discuss our critical accounting policies and estimates in Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” of our Annual Report on Form 10-K for the year ended December 31, 2017. There have been no material changes in our significant accounting policies or critical accounting policies and estimates since the year ended December 31, 2017, except for the adoption of new accounting standards as discussed elsewhere in this report.

Results of Operations

Comparison of the Three and Six Months Ended June 30, 2018 and June 30, 2017.

	Three-Months Ended June 30,						Change
	2018			2017			$000's			%
Revenues	$	3		$	-		$	3			0	%
Cost of goods sold		1			17			(16	)		-94	%
Gross profit (loss)		2			(17	)		19			-112	%
Operating expenses:
Research and development		974			2,022			(1,048	)		-52	%
Sales and marketing		360			816			(456	)		-56	%
General and administrative		894			1,649			(755	)		-46	%
Total operating expenses		2,228			4,487			(2,259	)		-50	%
Operating loss		(2,226	)		(4,504	)		2,278			-51	%
Other expense		(10	)		—			(10	)		0	%
Interest expense		(10	)		(4	)		(6	)		150	%
Loss before income tax provision		(2,246	)		(4,508	)		2,262			-50	%
Income tax provision		5			25			(20	)		-80	%
Net loss	$	(2,251	)	$	(4,533	)	$	2,282			-50	%

	Six-Months Ended June 30,						Change
	2018			2017			$000's			%
Revenues	$	7		$	5		$	2			40	%
Cost of goods sold		48			28			20			71	%
Gross loss		(41	)		(23	)		(18	)		78	%
Operating expenses:
Research and development		1,684			3,863			(2,179	)		-56	%
Sales and marketing		712			1,777			(1,065	)		-60	%
General and administrative		1,756			3,403			(1,647	)		-48	%
Total operating expenses		4,152			9,043			(4,891	)		-54	%
Operating loss		(4,193	)		(9,066	)		4,873			-54	%
Other income		(10	)		—			(10	)		0	%
Interest expense		(19	)		(18	)		(1	)		6	%
Loss before income tax provision		(4,222	)		(9,084	)		4,862			-54	%
Income tax provision		43			41			2			5	%
Net loss	$	(4,265	)	$	(9,125	)	$	4,860			-53	%

Revenue

Revenue for the three months ended June 30, 2018 was $3,000 as compared to $0 for the corresponding period in 2017. Revenue for the six months ended June 30, 2018 was $7,000 as compared to $5,000 for the corresponding period in 2017. Revenues were immaterial for both periods presented and are expected to continue to be immaterial in the near-term as we are in the near term undertaking limited commercialization efforts in only a few selected markets. Unless and until we receive FDA approval to sell and market our microlens within the United States, we are focusing our sales and marketing resources to sell our microlens to ophthalmic clinics primarily in Germany and South Korea.

Cost of Goods Sold

Cost of goods sold was $1,000 for the three months ended June 30, 2018 as compared to $17,000 in the three months ended June 30, 2017, or a decrease of $16,000 primarily due to the provisions for inventory obsolescence of $19,000 recorded in the three months ended June 30, 2017. For the six months ended June 30, 2018 and 2017, cost of goods sold was $48,000 and 28,000, respectively. Cost of sales includes inventory adjustments, such as a provision for inventory obsolescence, which can fluctuate from period to period depending upon the mix, the current shelf life of lens inventory in relation to our regulated policy and the size of our finished goods inventory. During the three months ended June 30, 2018 and 2017, we recorded additional provisions for inventory obsolescence and unfavorable adjustments of $0 and $19,000, respectively. For the six-month period ended June 30, 2018 and 2017, we recorded additional provisions for inventory obsolescence of $45,000 and $29,000, respectively.

Research and Development

Research and development expense declined by $1,048,000 or 52%, for the three months ended June 30, 2018 as compared to the same period in 2017. The decrease in research and development spend is primarily due to (i) a $336,000 cost decrease related to the currently discontinued development of our disposable inserter, (ii) a $216,000 cost decrease related to our U.S. clinical trials, (iii) $268,000 for lower manufacturing costs, and (iv) $228,000 for lower regulatory and quality assurance costs.

For the six months ended June 30, 2018, research and development expense declined by $2,179,000, or 56%, as compared to the same period in 2017. The decrease in research and development spend is primarily due to (i) a $556,000 cost decrease related to related to the currently discontinued development of our disposable inserter, (ii) a $504,000 cost decrease related to our U.S. clinical trials, (iii) 654,000 for lower allocated manufacturing costs, and (iv) $465,000 for lower regulatory and quality assurance costs.

During 2018, we expect that costs related to our U.S. staged pivotal clinical trial will decline as compared to 2017, primarily due to the main focus of the trial shifting from compliance to submission to the FDA of the remaining PMA modules and clinical data, and management’s decision to discontinue development of our disposable inserter.

Sales and Marketing

Sales and marketing expense decreased by $456,000 or 56%, for the three months ended June 30, 2018 as compared to the three months ended June 30, 2017. The decrease is primarily a result of lower advertising and promotional costs of $6,000, (ii) a $357,000 cost decrease related to lower employee compensation due to our reduced headcount, and (iii) other net cost decreases of $93,000 related to travel, compensation and other sales and marketing expenses.

For the six months ended June 30, 2018, sales and marketing expense declined by $1,065,000, or 60%, as compared to the same period in 2017. The decrease is primarily a result of lower advertising and promotional costs of $278,000, (ii) a $611,000 cost decrease related to lower employee compensation due to our reduced headcount, and (iii) other net cost decreases of $176,000 related to travel, compensation and other sales and marketing expenses.

We evaluated our commercialization strategy as part of the December 2017 re-prioritization of resources, which resulted in limiting our commercialization efforts to Germany and South Korea, and focusing our resources on completing our U.S. staged pivotal clinical trial.

General and Administrative

General and administrative expense declined by $755,000, or 46%, for the three months ended June 30, 2018 as compared to the same period in 2017. General and administrative expenses declined primarily due to (i) reduced personnel costs of $350,000, due to reduced headcount, (ii) reduced stock based compensation expense of $136,000, (i) lower professional fees of $101,000 and (iii) other net cost decreases of $168,000 related to travel, insurance and other administrative expenses.

For the six months ended June 30, 2018, general and administrative expense decreased by $1,647,000, or 48%, as compared to the same period in 2017. General and administrative expenses declined primarily due to (i) reduced personnel costs of $663,000, due to reduced headcount, (ii) reduced stock based compensation expense of $467,000, (i) lower professional fees of $230,000 and (iii) other net cost decreases of $287,000 related to travel, insurance and other administrative expenses.

Interest Expense, net

Interest expense for the three months ended June 30, 2018 was $6,000 higher than the same period in 2017. For the six months ended June 30, 2018, interest expense was $1,000 higher than the corresponding period in 2017. The change is due primarily to a decrease in interest expense related to the Neoptics asset purchase.

Net Loss

Our net loss of $2.3 million for the three months ended June 30, 2018 was $2.3 million lower, or 50% lower, than the net loss of $4.5 million in the corresponding period in 2017. For the six months ended June 30, 2018, our net loss was $4.3 million as compared to $9.1 million, or $4.9 million lower for the comparable period in 2017. We expect to incur significant additional future losses due to anticipated costs related to our U.S. staged pivotal clinical trial and ongoing costs required to develop the market for our microlens.

Liquidity and Capital Resources

At June 30, 2018, we had cash of $3.3 million, reflecting a $0.1 million increase from our cash balance at December 31, 2017 of $3.2 million. Our primary uses of cash are to fund operating expenses, primarily general and administrative expenditures and research and development expenditures. Cash used to fund operating expenses is impacted by the timing of when we pay these expenses, as reflected in the change in our outstanding accounts payable and accrued expenses. In April 2018, in a private placement, we sold 5,000 preferred shares to Richard Ressler, a member of the Board of Directors and our principal shareholder, for an aggregate purchase price of $5.0 million. In connection with this transaction, we granted a warrant to Ressler covering 1,953,125 ordinary shares exercisable over a five-year period with an exercise price of $2.56. The preferred shares accrue a dividend at the rate of 10% per annum during the first 18 months, 20% for months 19 through 24 and 30% from month 25 until such preferred shares are redeemed, payable in preferred shares on a quarterly basis. Undeclared dividends for the period from the date of issuance of April 12, 2018 to June 30, 2018 is 50,334 preferred shares.

Our future capital requirements are difficult to forecast and will depend on many factors, including:

•

the progress, timing, costs and completion of U.S. staged pivotal clinical trial;

•

the outcome, timing and cost of regulatory approvals;

•

delays that may be caused by changing regulatory requirements;

•

timing and amount of revenue resulting from sales to customers outside the US; and

•

timing and amount of investments in our commercialization efforts outside the U.S.

The following table summarizes our cash flows for the periods indicated:

	Six-Months Ended June 30,
	2018			2017
Net cash used in operating activities	$	(4,881	)	$	(7,127	)
Net cash used in investing activities	$	(2	)	$	(94	)
Net cash provided by financing activities	$	4,994		$	10,485

At June 30, 2018, we had an accumulated deficit of approximately $92.6 million and we expect to incur additional future operating losses. As we continue to incur losses, our transition to profitability will depend on the successful development, approval and commercialization of our microlens. We may never achieve profitability, and unless and until we do, we will need to continue to raise additional capital. Based on our current business plan, we believe that our cash and cash equivalents at June 30, 2018 will not be sufficient to meet our anticipated cash requirements during the twelve-month period subsequent to the issuance of the financial statements included in this Quarterly Report on Form 10-Q. We must raise additional capital to fund our operations. We may raise additional capital through equity offerings, debt financings, collaborations and/or licensing arrangements. Additional funds may not be available when we need them on terms that are acceptable to us, or at all. If adequate funds are not available on acceptable terms, we may be required to delay, reduce the scope of, or curtail, our operations. To the extent that we raise additional funds by issuing equity securities, our shareholders will experience dilution, and debt financing, if available, may involve restrictive covenants.

Off-Balance Sheet Arrangements

We have not entered into any off-balance sheet arrangements and do not have any holdings in variable interest entities.

Recent Accounting Pronouncements

Refer to Note 2, “Summary of Significant Accounting Policies,” of our notes to consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q for a discussion of new accounting standards.

ITEM 3.

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Under Securities and Exchange Commission, or SEC, rules and regulations, as a smaller reporting company we are not required to provide the information otherwise required by this item.

ITEM 4.

CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our Chief Executive Officer and Chief Accounting Officer, has evaluated the effectiveness of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended) as of the end of the period covered by this Quarterly Report on Form 10-Q. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost benefit relationship of possible controls and procedures. Based on such evaluation, our Chief Executive Officer and Chief Accounting Officer have concluded that, as of the end of the period covered by this report, our disclosure controls and procedures were effective.

Changes in Internal Control over Financial Reporting

There was no change in our internal control over financial reporting identified in connection with the evaluation required by Rule 13a-15(d) and 15d-15(d) of the Exchange Act that occurred during the quarter ended June 30, 2018 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II. OTHER INFORMATION

ITEM 1.

LEGAL PROCEEDINGS

We are not aware of any pending or threatened legal proceeding against us that could have a material adverse effect on our business, operating results or financial condition. However, the medical device industry is characterized by frequent claims and litigation, including claims regarding patent and other intellectual property rights as well as improper hiring practices. As a result, we may be involved in various legal proceedings from time to time.

ITEM 1A.

RISK FACTORS

Please refer to “Part I, Item 1A. Risk Factors” of our Annual Report on Form 10-K for the year ended December 31, 2017, filed with the Securities and Exchange Commission on March 20, 2018 for a description of certain significant risks and uncertainties to which our business, operations and financial condition are subject. Except as described below there have been no material changes to these risk factors.

We are required to meet the NASDAQ Capital Market’s continued listing requirements and other NASDAQ rules, or we may risk delisting. Delisting could negatively affect the price of our ordinary shares, which could make it more difficult for us to sell securities in a future financing or for you to sell our ordinary shares.

We are required to meet the continued listing requirements of the NASDAQ Capital Market and other NASDAQ rules, including but not limited to those regarding director independence and independent committee requirements, minimum stockholders’ equity on minimum market value of listed securities, minimum share price and certain other corporate governance requirements. In particular, we are required to maintain a minimum stockholders’ equity of $2.5 million or a minimum market value of listed securities of $35.0 million. As of June 30, 2018, our stockholders’ equity was approximately $3.8 million and the market value of our listed securities was approximately $36.8 million. If we do not continue to meet these continued listing requirements, our ordinary shares could be delisted. Delisting from the NASDAQ Capital Market would cause us to pursue eligibility for trading of these securities on other markets or exchanges, or on the “pink sheets.” In such case, our stockholders’ ability to trade, or obtain quotations of the market value of our ordinary shares may be severely limited because of lower trading volumes and transaction delays. These factors could contribute to lower prices and larger spreads in the bid and ask prices of these securities. There can be no assurance that our securities, if delisted from the NASDAQ Capital Market in the future, would be listed on a national securities exchange, a national quotation service, the over-the-counter markets or the pink sheets. Delisting from the NASDAQ Capital Market, or even the issuance of a notice of potential delisting, would also result in negative publicity, make it more difficult for us to raise additional capital, adversely affect the market price and liquidity of our ordinary shares, decrease securities analysts’ coverage of us or diminish investor, supplier and employee confidence.

ITEM 2.

UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

None.

ITEM 3.

DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4.

MINE SAFETY DISCLOSURES

Not Applicable

ITEM 5.

OTHER INFORMATION

None.

ITEM 6.

EXHIBITS

Exhibit Number		Exhibit Description

31.1+		Certification of Principal Executive Officer Required by Rule 13a-14(a) of the Securities Exchange Act of 1934, as amended, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2+		Certification of Principal Financial Officer Required by Rule 13a-14(a) of the Securities Exchange Act of 1934, as amended, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32.1*		Certification of Chief Executive Officer and Chief Accounting Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101.INS+		XBRL Instance

101.SCH+		XBRL Taxonomy Extension Schema

101.CAL+		XBRL Taxonomy Extension Calculation

101.DEF+		XBRL Taxonomy Extension Definition

101.LAB+		XBRL Taxonomy Extension Label

101.PRE+		XBRL Taxonomy Extension Presentation

+	Indicates filed herewith.

*	Indicates furnished herewith

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	PRESBIA PLC

Date: August 10, 2018	By:	/s/ Mark Yung
		Mark Yung
		President and Chief Executive Officer

Date: August 10, 2018	By:	/s/ Richard Fogarty
		Richard Fogarty
		Chief Accounting Officer,
		Vice President, Finance and Secretary

EX-31.1 2 lens-ex311_7.htm EX-31.1 lens-ex311_7.htm

Exhibit 31.1

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER REQUIRED BY

RULE 13A-14(A) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED,

AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Mark Yung, certify that:

1.	I have reviewed this Quarterly Report on Form 10-Q of Presbia PLC;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 10, 2018	By:	/s/ Mark Yung
		Mark Yung
		Chief Executive Officer

EX-31.2 3 lens-ex312_6.htm EX-31.2 lens-ex312_6.htm

Exhibit 31.2

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER REQUIRED BY

RULE 13A-14(A) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED,

AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Richard Fogarty, certify that:

1.	I have reviewed this Quarterly Report on Form 10-Q of Presbia PLC;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

(a)

(b)

(c)

(d)

5.	The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 10, 2018	By:	/s/ Richard Fogarty
		Richard Fogarty
		Chief Accounting Officer

EX-32.1 4 lens-ex321_8.htm EX-32.1 lens-ex321_8.htm

Exhibit 32.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Presbia PLC (the “Company”) for the quarterly period ended June 30, 2018 (the “Report”), the undersigned hereby certify in their capacities as Chief Executive Officer and Chief Accounting Officer of the Company, respectively, pursuant to 18 U.S.C. section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: August 10, 2018	By:	/s/ Mark Yung
		Mark Yung
		Chief Executive Officer
		(Principle Executive Officer)

Date: August 10, 2018	By:	/s/ Richard Fogarty
		Richard Fogarty
		Chief Accounting Officer
		(Principle Financial Officer)

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signatures that appear in typed form within the electronic version of this written statement required by Section 906, has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

EX-101.INS 5 lens-20180630.xml XBRL INSTANCE DOCUMENT shares iso4217:USD iso4217:USD shares iso4217:EUR shares pure lens:Facility 0001591096 2018-01-01 2018-06-30 0001591096 2018-08-10 0001591096 2018-06-30 0001591096 2017-12-31 0001591096 us-gaap:SeriesAPreferredStockMember 2018-06-30 0001591096 us-gaap:SeriesAPreferredStockMember 2017-12-31 0001591096 lens:USAPreferredSharesMember 2018-06-30 0001591096 lens:USAPreferredSharesMember 2017-12-31 0001591096 2018-04-01 2018-06-30 0001591096 2017-01-01 2017-06-30 0001591096 2017-04-01 2017-06-30 0001591096 2016-12-31 0001591096 2017-06-30 0001591096 lens:NonEmployeeStockOptionMember 2018-01-01 2018-06-30 0001591096 lens:LensesMember 2018-01-01 2018-06-30 0001591096 lens:AccessoriesMember 2018-01-01 2018-06-30 0001591096 srt:MinimumMember 2018-01-01 2018-06-30 0001591096 srt:MaximumMember 2018-01-01 2018-06-30 0001591096 us-gaap:GeneralAndAdministrativeExpenseMember 2018-04-01 2018-06-30 0001591096 us-gaap:GeneralAndAdministrativeExpenseMember 2017-04-01 2017-06-30 0001591096 us-gaap:GeneralAndAdministrativeExpenseMember 2018-01-01 2018-06-30 0001591096 us-gaap:GeneralAndAdministrativeExpenseMember 2017-01-01 2017-06-30 0001591096 2017-01-01 2017-12-31 0001591096 lens:PresbiaIncentivePlanMember 2015-01-13 2015-01-14 0001591096 lens:PresbiaIncentivePlanMember 2015-01-14 0001591096 lens:PresbiaIncentivePlanMember 2018-06-30 0001591096 lens:PresbiaIncentivePlanMember 2018-01-01 2018-06-30 0001591096 lens:PresbiaIncentivePlanMember lens:OverFiveYearPeriodMember 2015-01-13 2015-01-14 0001591096 us-gaap:ResearchAndDevelopmentExpenseMember 2018-04-01 2018-06-30 0001591096 us-gaap:ResearchAndDevelopmentExpenseMember 2017-04-01 2017-06-30 0001591096 us-gaap:ResearchAndDevelopmentExpenseMember 2018-01-01 2018-06-30 0001591096 us-gaap:ResearchAndDevelopmentExpenseMember 2017-01-01 2017-06-30 0001591096 us-gaap:SellingAndMarketingExpenseMember 2018-04-01 2018-06-30 0001591096 us-gaap:SellingAndMarketingExpenseMember 2017-04-01 2017-06-30 0001591096 us-gaap:SellingAndMarketingExpenseMember 2018-01-01 2018-06-30 0001591096 us-gaap:SellingAndMarketingExpenseMember 2017-01-01 2017-06-30 0001591096 us-gaap:EmployeeStockOptionMember 2017-04-01 2017-06-30 0001591096 us-gaap:EmployeeStockOptionMember 2017-01-01 2017-06-30 0001591096 us-gaap:EmployeeStockOptionMember 2018-04-01 2018-06-30 0001591096 us-gaap:EmployeeStockOptionMember 2018-01-01 2018-06-30 0001591096 us-gaap:EmployeeStockOptionMember lens:OverFiveYearPeriodMember 2018-04-01 2018-06-30 0001591096 us-gaap:EmployeeStockOptionMember lens:OverFiveYearPeriodMember 2018-01-01 2018-06-30 0001591096 lens:NonEmployeeConsultantsAndMedicalAdvisorsMember 2018-04-01 2018-06-30 0001591096 lens:NonEmployeeConsultantsAndMedicalAdvisorsMember 2018-01-01 2018-06-30 0001591096 lens:NonEmployeeConsultantsAndMedicalAdvisorsMember 2017-04-01 2017-06-30 0001591096 lens:NonEmployeeConsultantsAndMedicalAdvisorsMember 2017-01-01 2017-06-30 0001591096 lens:NonEmployeeStockOptionMember srt:MinimumMember 2018-04-01 2018-06-30 0001591096 lens:NonEmployeeStockOptionMember srt:MaximumMember 2018-04-01 2018-06-30 0001591096 lens:NonEmployeeStockOptionMember srt:MinimumMember 2017-04-01 2017-06-30 0001591096 lens:NonEmployeeStockOptionMember srt:MaximumMember 2017-04-01 2017-06-30 0001591096 lens:NonEmployeeStockOptionMember srt:MinimumMember 2018-01-01 2018-06-30 0001591096 lens:NonEmployeeStockOptionMember srt:MaximumMember 2018-01-01 2018-06-30 0001591096 lens:NonEmployeeStockOptionMember srt:MinimumMember 2017-01-01 2017-06-30 0001591096 lens:NonEmployeeStockOptionMember srt:MaximumMember 2017-01-01 2017-06-30 0001591096 lens:NonEmployeeStockOptionMember 2018-04-01 2018-06-30 0001591096 lens:NonEmployeeStockOptionMember 2017-04-01 2017-06-30 0001591096 lens:NonEmployeeStockOptionMember 2017-01-01 2017-06-30 0001591096 lens:MedicalAdvisoryBoardCompensationMember 2018-01-01 2018-06-30 0001591096 lens:MedicalAdvisoryBoardCompensationMember 2018-06-30 0001591096 us-gaap:RestrictedStockMember 2017-12-31 0001591096 us-gaap:RestrictedStockMember 2018-01-01 2018-06-30 0001591096 us-gaap:RestrictedStockMember 2018-06-30 0001591096 us-gaap:RestrictedStockUnitsRSUMember 2018-01-01 2018-06-30 0001591096 us-gaap:ShareBasedCompensationAwardTrancheOneMember us-gaap:RestrictedStockUnitsRSUMember 2018-01-01 2018-06-30 0001591096 us-gaap:ShareBasedCompensationAwardTrancheTwoMember us-gaap:RestrictedStockUnitsRSUMember 2018-01-01 2018-06-30 0001591096 us-gaap:ShareBasedCompensationAwardTrancheThreeMember us-gaap:RestrictedStockUnitsRSUMember 2018-01-01 2018-06-30 0001591096 lens:ShareBasedCompensationAwardTrancheFourMember us-gaap:RestrictedStockUnitsRSUMember 2018-01-01 2018-06-30 0001591096 lens:ShareBasedCompensationAwardTrancheFiveMember us-gaap:RestrictedStockUnitsRSUMember 2018-01-01 2018-06-30 0001591096 us-gaap:RestrictedStockUnitsRSUMember 2017-12-31 0001591096 us-gaap:RestrictedStockUnitsRSUMember 2018-06-30 0001591096 lens:EmployeeAndNonEmployeeMember 2018-06-30 0001591096 lens:EmployeeAndNonEmployeeMember 2017-06-30 0001591096 us-gaap:RestrictedStockMember 2017-01-01 2017-06-30 0001591096 lens:EmployeeAndNonEmployeeMember 2018-01-01 2018-06-30 0001591096 lens:EmployeeAndNonEmployeeMember 2017-01-01 2017-06-30 0001591096 us-gaap:RestrictedStockUnitsRSUMember 2017-01-01 2017-06-30 0001591096 us-gaap:RestrictedStockMember 2017-06-30 0001591096 us-gaap:RestrictedStockUnitsRSUMember 2017-06-30 0001591096 lens:FederalDepositInsuranceCorporationMember srt:MaximumMember 2018-06-30 0001591096 us-gaap:SupplierConcentrationRiskMember us-gaap:CostOfGoodsTotalMember 2018-01-01 2018-06-30 0001591096 country:IE us-gaap:ForeignCountryMember 2018-06-30 0001591096 country:IE us-gaap:ForeignCountryMember 2017-12-31 0001591096 lens:RichardResslerMember us-gaap:PreferredStockMember us-gaap:PrivatePlacementMember srt:ParentCompanyMember 2018-04-12 2018-04-12 0001591096 lens:RichardResslerMember us-gaap:PreferredStockMember us-gaap:PrivatePlacementMember lens:PresbiaUSAIncMember 2018-04-12 2018-04-12 0001591096 lens:RichardResslerMember us-gaap:PreferredStockMember us-gaap:PrivatePlacementMember 2018-04-12 2018-04-12 0001591096 lens:RichardResslerMember 2018-04-12 0001591096 lens:RichardResslerMember 2018-04-12 2018-04-12 0001591096 lens:FirstEighteenMonthsMember 2018-04-12 2018-04-12 0001591096 lens:NineteenThroughTwentyFourMonthsMember 2018-04-12 2018-04-12 0001591096 lens:TwentyFifthMonthAndThereafterMember 2018-04-12 2018-04-12 0001591096 2018-04-12 2018-06-30 0001591096 2018-04-12 0001591096 stpr:CA 2012-05-31 0001591096 stpr:CA 2012-05-30 2012-05-31 0001591096 stpr:CA 2016-06-01 0001591096 stpr:CA 2016-06-01 2016-06-01 0001591096 country:IE 2013-12-01 0001591096 country:IE 2013-12-01 2013-12-01 0001591096 country:NL 2016-01-02 0001591096 country:NL 2016-01-01 2016-01-02 0001591096 stpr:CA lens:ReorganizationMember 2017-12-01 2017-12-31 0001591096 stpr:CA lens:ReorganizationMember 2017-12-31 0001591096 stpr:CA lens:ReorganizationMember 2017-01-01 2017-12-31 10-Q false 2018-06-30 2018 Q2 LENS PRESBIA PLC 0001591096 --12-31 Smaller Reporting Company 17157160

3328000

3236000

23000

8000

71000

127000

305000

108000

3727000

3479000

410000

477000

1411000

1479000

77000

127000

5625000

5562000

471000

628000

35000

23000

482000

480000

744000

1151000

1732000

2282000

98000

107000

12000

25000

30000

1855000

2431000

17000

54000 54000

96266000

91362000

-92567000

-88302000

3770000

3131000

5625000

5562000

0.001

50000000

100

0.01

8000

4900

0.001

350000000

17157160

17121857

1.00 1.00 1.35 1.35 39994 39994 39994 39994 39994 39994

3000

7000

5000

us-gaap:ProductMember

1000

17000

48000

28000

us-gaap:ProductMember

2000

-17000

-41000

-23000

974000

2022000

1684000

3863000

360000

816000

712000

1777000

894000

1649000

1756000

3403000

2228000

4487000

4152000

9043000

-2226000

-4504000

-4193000

-9066000

-10000

-4000

-19000

-18000

-2246000

-4508000

-4222000

-9084000

5000

25000

43000

41000

-2251000

-4533000

-4265000

-9125000

-0.13

-0.27

-0.25

-0.58

17079548

16956056

17042358

15618001

-4265000

-9125000

126000

171000

45000

29000

8000

1038000

-9000

21000 40000

15000

7000

-11000

-24000

196000

100000

-50000

2000

-747000

698000

69000

39000

-9000

58000

12000

10000

-4881000

-7127000

2000

87000

7000

-2000

-94000

10485000

4994000

10485000

111000

3264000

-19000

71000

7333000

10668000

<div> (1)  Basis of Presentation Principles of Consolidation.  The accompanying consolidated financial statements have been derived from the historical cost basis of the assets and liabilities, financial condition and cash flows of Presbia PLC and Presbia Ireland, Limited, both organized in Ireland, Presbia Investments, a wholly-owned subsidiary of Presbia PLC organized in the Cayman Islands, and Presbia Ireland, Limited’s subsidiaries, Presbia Deutchland GmbH, Presbia USA, Inc., and OPL, LLC. Presbia Deutchland GmbH is organized in Germany, and Presbia USA, Inc. and OPL, LLC are both entities organized in the United States, and include Presbia USA, Inc.’s subsidiaries, Visitome, Inc. and PresbiBio, LLC, both organized in the United States, and OPL, LLC’s direct and indirect subsidiaries, PIP Holdings, C.V and Presbia Cooperatief U.A., both organized in the Netherlands, and PresbiOptical LLC, organized in the United States (collectively, including Presbia PLC, the “Company”).  The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”).  The Company’s fiscal year ends on December 31. The entities presented in the consolidated financial statements have been under common control during the periods presented. All intercompany accounts have been eliminated in consolidation. Basis of Presentation.  The accompanying unaudited consolidated financial statements as of June 30, 2018 and for the three and six months ended June 30, 2018 and 2017, respectively, have been prepared in accordance with United States generally accepted accounting principles (“U.S.GAAP”) for interim financial reporting, and with the instructions to Form 10-Q and Article 8 of Regulation S-X. The accompanying consolidated balance sheet at December 31, 2017 has been derived from the audited consolidated balance sheet at December 31, 2017, contained in the annual report on Form 10-K for the year ended December 31, 2017. These consolidated financial statements should be read in conjunction with the audited consolidated financial statements presented in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2017, filed with the Securities and Exchange Commission on March 30, 2018. In the opinion of management, the accompanying consolidated financial statements reflect all adjustments which are necessary for a fair presentation of the results of operations and cash flows for the periods presented. The results of operations for such interim periods are not necessarily indicative of results of operations to be expected for the full year. References to amounts in the consolidated financial statement sections are in thousands, except per share data, unless otherwise specified. Liquidity At June 30, 2018, the Company has an accumulated deficit of $92.6 million and it expects to incur significant additional future operating losses. As it continues to incur losses, the Company’s transition to profitability will depend on the successful development, approval and commercialization of its microlens. The Company may never achieve profitability, and unless and until it does, it will need to continue to raise additional capital. Based on the Company’s current business plan, management believes that its cash and cash equivalents at June 30, 2018 will not be sufficient to meet its anticipated cash requirements during the twelve-month period subsequent to the issuance of the financial statements included in this Quarterly Report on Form 10-Q.  These factors raise substantial doubt about the Company’s ability to continue as a going concern within one year from the date this Quarterly Report on Form 10-Q is filed with the U.S. Securities and Exchange Commission (SEC). The Company’s current commercialization strategy is targeted to countries where the Company can establish the market for its technology.  This commercialization strategy will undergo continual prioritization and in the future the Company may adjust its commercialization efforts to preserve its existing cash or realize better results than anticipated which could have a positive impact on cash.  The Company’s U.S. pivotal clinical trial and planned FDA approval is its highest priority. The Company must raise additional capital to fund its operations.  It plans to raise additional capital through equity offerings, debt financings, collaborations and/or licensing arrangements. Additional funds may not be available when the Company needs them on terms that are acceptable to the Company, or at all. If adequate funds are not available on acceptable terms, the Company may be required to delay, reduce the scope of, or curtail, its operations. To the extent that the Company raises additional funds by issuing equity securities, its shareholders will experience dilution, and debt financing, if available, may involve restrictive covenants.</div>

<div> (3)  Loss per Share Basic net loss per ordinary share is calculated by dividing net loss allocated to ordinary shareholders by the weighted average number of ordinary shares outstanding during the reporting period, excluding unvested restricted stock awards. Diluted net loss allocated to ordinary shareholders per share is calculated based on the weighted average number of Ordinary Shares and dilutive potential Ordinary Shares outstanding during the period.  Dilutive potential ordinary shares consist of the shares issuable upon the exercise of options and upon the vesting of restricted shares under the treasury stock method.  In net loss periods, basic and diluted net loss per share are identical since the effect of potential ordinary shares is anti-dilutive and therefore excluded. Basic and diluted loss per share for the three and six months ended June 30, 2018 and 2017 were calculated as follows:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:79.68%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.14%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.24%; border-bottom:solid 0.75pt transparent;">  </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.72%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Three-Months Ended June 30,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.24%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.74%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Six-Months Ended June 30,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.14%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.24%; border-bottom:solid 0.75pt transparent;">  </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2018</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2017</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.24%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2018</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.24%; border-top:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2017</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.14%;"> Net Loss</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.24%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%; border-top:solid 0.75pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.8%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,251</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;white-space:nowrap;"> )</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.24%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%; border-top:solid 0.75pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.8%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,533</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;white-space:nowrap;"> )</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.24%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%; border-top:solid 0.75pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.8%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,265</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;white-space:nowrap;"> )</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.24%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%; border-top:solid 0.75pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.8%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(9,125</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;white-space:nowrap;"> )</td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.14%;"> Weighted average shares outstanding    - basic and diluted</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.24%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.8%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,079,548</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.24%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.8%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,956,056</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.24%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.8%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,042,358</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.24%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.8%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,618,001</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.14%;"> Net loss per ordinary share    - basic and diluted</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.24%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.8%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.13</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;white-space:nowrap;"> )</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.24%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.8%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.27</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;white-space:nowrap;"> )</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.24%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.8%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.25</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;white-space:nowrap;"> )</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.24%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.8%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.58</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;white-space:nowrap;"> )</td> </tr> </table></div>   Antidilutive securities, which consist of options and unvested restricted shares that are not included in the diluted net loss per share calculation, consisted of an aggregate of 1,049,795 and 1,152,500 weighted average shares for the three months ended June 30, 2018 and 2017, respectively and 972,019 and 1,050,000 for the six months ended June 30, 2018 and 2017, respectively.</div>

<div> (4)  Equity Based Awards Equity Issued by Presbia PLC Presbia Incentive Plan On January 14, 2015, the Company approved a compensation incentive plan (the “Presbia Incentive Plan”). The Presbia Incentive Plan permits the Company to grant awards of options, restricted shares, share appreciation rights, restricted share units, performance shares, performance share units, dividend equivalent rights in respect of awards and other share-based and cash-based awards, including annual and long-term cash incentive awards.  A total of 2,200,000 ordinary shares are authorized for issuance under the Presbia Incentive Plan of which approximately 367,591 were available on June 30, 2018 for future grants and awards. The exercise price of each option award shall be determined by the Board of Directors (or a committee thereof) at the date of grant in accordance with the terms of the 2005 Plan, and under the Presbia Incentive Plan awards generally vest 20% annually over a five-year period and expire no later than 10 years from the grant date.  The Presbia Incentive Plan terminates on January 14, 2025, unless terminated earlier by the board of directors.  Awards under the Presbia Incentive Plan may be granted to employees, directors, consultants and other persons who perform services for the Company or a subsidiary of the Company. The following table shows share-based compensation expense based upon all equity awards issued by Presbia PLC included in the Consolidated Statements of Operations for the three and six months ended June 30, 2018 and 2017. The Company recorded a credit of $86,000 and $524,000 as a result of the reversal of stock-based compensation for participants whose relationship with the Company terminated in the three and six months ended June 30, 2018, respectively.     <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.52%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">  </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.62%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Three-Months Ended June 30,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">  </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.62%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Six-Months Ended June 30,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.52%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">  </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2018</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2017</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%;">  </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2018</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-top:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2017</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.52%;"> Research and development</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(49</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> )</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">126</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(227</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> )</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">242</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.52%;"> General and administrative</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">174</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">311</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">175</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">641</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.52%; border-bottom:solid 0.75pt transparent;"> Sales and marketing</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">78</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">155</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.52%; border-bottom:double 2.5pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">155</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">515</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,038</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">  </td> </tr> </table></div>   Options The following table sets forth the Company’s option activity for the six months ended June 30, 2018:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.36%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.9%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.3%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Number of <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Presbia PLC <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Shares</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.9%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.3%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Weighted Average <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Exercise Price <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Per Share</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.9%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.3%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Aggregate <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic Value</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.36%;"> Balance, January 1, 2018</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.3%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">849,100</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.3%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.77</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.3%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.36%;"> Granted</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.3%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">365,000</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> $ </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.3%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.38</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.3%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.36%;"> Exercised</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.3%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.3%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.3%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.36%; border-bottom:solid 0.75pt transparent;"> Forfeited/cancelled/expired</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.9%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(71,450</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> )</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.9%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.38</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.9%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:15.3%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.36%; border-bottom:double 2.5pt transparent;"> Balance, June 30, 2018</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.9%; border-bottom:double 2.5pt transparent;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,142,650</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.9%; border-bottom:double 2.5pt transparent;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.44</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.9%; border-bottom:double 2.5pt transparent;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:15.3%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.36%;"> Vested, June 30, 2018</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.3%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">726,150</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.3%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.82</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.3%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.36%;"> Non Vested, June 30, 2018</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.3%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">416,500</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.3%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.27</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.3%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.36%;"> Exercisable, June 30, 2018</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.3%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">726,150</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.3%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.82</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.3%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> </tr> </table></div>   Employee Options The Company utilizes the Black-Scholes valuation model for estimating the fair value of granted stock options with the following assumptions in addition to the closing price of the Company’s ordinary shares on the date of the grant: (i) the Company estimates the expected term of the option utilizing the simplified method because of its limited history of option exercise activity and its options meet the criteria of a "plain-vanilla" option as defined by the Securities Exchange Commission (ii) due to its limited stock price volatility history, the Company uses a peer group average as permitted under Accounting Standards Codification (“ASC”) 718 consistent with the expected term of the stock option at the time of the grant and (iii) applies a risk-free interest rate based on the U.S. Treasury securities yield consistent with the expected term of the option at the time of the grant. The simplified method calculates the expected term as the average of the weighted average vesting period and contractual terms of the award. For those options granted to employees, stock-based compensation expense was based upon the fair value of the option as of the grant-date and attributed to future reporting periods on a straight-line basis over the vesting period, or the requisite service period. The Company adopted ASU 2016-09 on January 01, 2018, electing to account for forfeitures when they occur. The Company issued 365,000 and 0 employee options during the three and six months ended June 30, 2018. Options granted in 2018 vest 20% annually over a five-year period and expire 6.75 years from the grant date. The Company did not issue employee options during the three and six months ended June 30, 2017.   Non-Employee Options During the three and six months ended June 30, 2018 and 2017, the Company did not grant options to non-employee consultants and medical advisors. In contrast to the determination of the fair value of options granted to employees, which are determined based upon the grant-date assumptions and applying the Black-Scholes model, the fair values for non-employee options and the related stock-based compensation expense are remeasured each financial reporting period based upon the assumptions applicable on the dates in which the financial statements are prepared, which are disclosed in the following table:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80.76%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.48%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">  </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.22%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Three-Months Ended June 30,</td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;">  </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">  </td> <td colspan="7" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.66%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Six-Months Ended June 30,</td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:28.48%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">  </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.76%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2018</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.74%;">  </td> <td colspan="3" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.9%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2017</td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">  </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.26%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2018</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%;">  </td> <td colspan="3" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.86%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2017</td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock price per share</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.76%; border-top:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$0.85 - $1.13</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.74%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="3" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.9%; border-top:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$1.25 - $1.63</td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.26%; border-top:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$0.85 - $1.95</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="3" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.86%; border-top:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$1.25 - $2.51</td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.76%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.6 - 7.1 Yrs.</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.74%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="3" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.9%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.7 - 8.4 Yrs</td> <td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.26%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.6 - 7.4 Yrs.</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="3" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.86%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.7 - 8.6 Yrs</td> <td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Volatility</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.76%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72.9% - 77.3%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.74%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="3" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.9%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">79.1% - 83.5%</td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.26%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72.9% - 77.3%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="3" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.86%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">79.1% - 90.0%</td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dividends</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.74%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.36%;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.96%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free rate</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.76%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.8%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.74%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="3" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.9%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.2%</td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.26%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.6% - 2.8%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="3" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.86%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.2% - 2.3%</td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%;white-space:nowrap;">  </td> </tr> </table></div>   Because the performance criteria of these grants is based solely upon a requisite service period, but are subject to forfeiture if the service conditions are not met, stock-based compensation expense is determined by a straight-line attribution of the remeasured expense (mark-to-market) over the requisite service period subject to an adjustment to previously recognized expense in the event forfeitures occur. Restricted Shares  . The Company awarded 23,255 ordinary shares to the head of the Company’s medical advisory board as compensation for services provided during the six-month period ended June 30, 2018. The number of shares was determined by the closing price of $2.15 on June 29, 2018. The following table sets forth the Company’s restricted share activity for the three and six months ended June 30, 2018:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.72%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.5%; border-bottom:solid 0.75pt transparent;">  </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.62%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Unvested Number of <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Shares</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.5%; border-bottom:solid 0.75pt transparent;">  </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.62%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Weighted Average Fair <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Value per Share</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.72%;"> Balance, December 31, 2017</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.5%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.62%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">134,367</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.5%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.62%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.78</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.72%;"> Granted</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.5%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.62%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,255</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.5%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.62%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.15</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.72%;"> Vested</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.5%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.62%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(104,731</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> )</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.5%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.62%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.02</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.72%; border-bottom:solid 0.75pt transparent;"> Forfeited/cancelled</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.5%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.62%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.5%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.62%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.72%; border-bottom:double 2.5pt transparent;"> Unvested, June 30, 2018</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.5%; border-bottom:double 2.5pt transparent;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.62%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52,891</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.5%; border-bottom:double 2.5pt transparent;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.62%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.45</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">  </td> </tr> </table></div>   Restricted Share Units During the three and six months ended June 30, 2018, the Board of Directors did not award restricted share units (“RSU” or “RSU’s” or “RSU Plan”) to officers and employees in accordance with the guidelines provided by the Presbia Incentive Plan, which includes a provision that the recipient must be employed as a condition of vesting. The Presbia RSU Plan authorizes the issuance of 20% of each recipient’s total RSU award for the first occurrence that the closing price of the Company’s ordinary shares exceed, for a period of 20 consecutive business days, price thresholds of $10.00, $15.00, $20.00, $25.00 and $30.00, respectively. The RSU Plan also provides for a one-year “wait” or service period prior to any vesting permitted under the plan. The RSU Plan has a seven-year expiration period following the date of the grant. Fair value of the RSU’s awarded are determined using a Monte Carlo Simulation (“MCS”) methodology, which considers the separate probabilities that each of the price thresholds or market conditions will be achieved under the RSU Plan guidelines. Each probability is weighted by its respective price threshold, or its intrinsic value, which provides the basis for an aggregate fair value. The Company used the following key inputs in determining the fair value using the MCS model: (i) the volatility of the entity’s common stock and (ii) the closing price of the entity’s stock as of the measurement date of the RSU award. In accordance with GAAP, the Company recognizes as stock-based compensation expense, using a straight-line attribution method, the aggregate fair value over future periods based upon the respective derived service periods and fair values for each of the price thresholds as provided by the MCS model. The following table sets forth the Company’s RSU activity for the six months ended June 30, 2018:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.42%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.36%; border-bottom:solid 0.75pt transparent;">  </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.4%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Unvested Number of <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Shares</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.36%; border-bottom:solid 0.75pt transparent;">  </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.4%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Weighted Average Fair <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Value per Share</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.42%;"> Balance, December 31, 2017</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.4%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">739,000</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.4%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.09</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.42%;"> Granted</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.4%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.4%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.42%;"> Vested</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.4%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.4%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.42%; border-bottom:solid 0.75pt transparent;"> Forfeited/cancelled</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.36%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.4%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(226,000</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> )</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.36%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.4%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.44</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.42%; border-bottom:double 2.5pt transparent;"> Unvested, June 30, 2018</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.36%; border-bottom:double 2.5pt transparent;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.4%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">513,000</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.36%; border-bottom:double 2.5pt transparent;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.4%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.32</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">  </td> </tr> </table></div>   Unrecognized Share-based Compensation As of June 30, 2018 and 2017, there were $785,000 and $2,740,000, respectively, of unrecognized compensation expense related to employee and non-employee options of the Company, which collectively is expected to be recognized by the Company over the weighted average vesting period of 2.3 and 1.7 years, respectively. Unrecognized compensation expense for the same periods related to restricted shares was $226,000 and $290,000, respectively, and is expected to be recognized over the weighted average vesting periods of 1.8 and 1.5 years, respectively. As of June 30, 2018 and 2017, there was approximately $513,000 and 7,710,000 of unrecognized compensation expense with respect to the RSU’s over a weighted average remaining derived service period of 0.9 and 2.4 years, respectively.  </div>

<div> (6) Income Taxes Deferred income tax assets and liabilities are recognized for temporary differences between financial statement and income tax carrying values, using tax rates in effect for the years such differences are expected to reverse. Due to uncertainties surrounding the Company's ability to generate future taxable income and consequently realize such deferred income tax assets, a full valuation allowance has been established. The Company continues to maintain a full valuation allowance against its deferred tax assets as of June 30, 2018. <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The impact of an uncertain income tax position on the income tax return must be recognized at the largest amount that is more likely than not to be sustained upon audit by the relevant tax authority. An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained. In December 2017, the Company recorded a liability of $199,000 with respect to unpaid Irish income taxes in accordance with ASC 740-10, , Accounting for Uncertainty of Income Taxes, and increased that liability during the six months ended June 30, 2018 to $274,000. The Company’s policy is to recognize interest expense and penalties related to income tax matters as a component of the income tax provision. As of June 30, 2018 and December 31, 2017, the Company had $35,000 and $39,000, respectively, of tax related accrued interest and penalties on its consolidated balance sheet or on its consolidated statement of operations.     A reconciliation of gross unrecognized tax benefits is as follows:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:76.19%;"> <tr> <td style="width:41.67%;"></td> <td style="width:0.19%;"></td> <td style="width:0.06%;"></td> <td style="width:1.06%;"></td> <td style="width:13.52%;"></td> <td style="width:2.21%;"></td> <td style="width:1.06%;"></td> <td style="width:15.6%;"></td> <td style="width:0.84%;"></td> </tr> <tr style="height:1pt;"> <td valign="bottom" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;white-space:nowrap;">  </td> <td valign="top">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td colspan="4" valign="bottom">  </td> </tr> <tr style="height:1pt;"> <td valign="bottom" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> <td valign="top" style=" border-bottom:solid 0.75pt transparent;">  </td> <td valign="top" style=" border-bottom:solid 0.75pt transparent;">  </td> <td valign="top" style=" border-bottom:solid 0.75pt #000000;">  </td> <td valign="bottom" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">June 30, 2018</td> <td valign="bottom" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> <td valign="top" style=" border-bottom:solid 0.75pt #000000;">  </td> <td valign="bottom" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2017</td> </tr> <tr style="height:1pt;"> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;white-space:nowrap;"> Balance at the beginning of the year</td> <td valign="top" bgcolor="#CFF0FC">  </td> <td valign="top" bgcolor="#CFF0FC">  </td> <td valign="top" bgcolor="#CFF0FC" style=" border-top:solid 0.75pt #000000;">  </td> <td valign="top" bgcolor="#CFF0FC" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">199,000</td> <td valign="top" bgcolor="#CFF0FC" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;white-space:nowrap;">  </td> <td valign="top" bgcolor="#CFF0FC">  </td> <td valign="top" bgcolor="#CFF0FC" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC">  </td> </tr> <tr style="height:1pt;"> <td valign="bottom" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> Increases related to current year tax positions</td> <td valign="top" style=" border-bottom:solid 0.75pt transparent;">  </td> <td valign="top" style=" border-bottom:solid 0.75pt transparent;">  </td> <td valign="top" style=" border-bottom:solid 0.75pt #000000;">  </td> <td valign="bottom" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75,000</td> <td valign="bottom" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> <td valign="top" style=" border-bottom:solid 0.75pt #000000;">  </td> <td valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">199,000</td> <td valign="bottom" style=" border-bottom:solid 0.75pt transparent;">  </td> </tr> <tr style="height:1pt;"> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;white-space:nowrap;"> Balance at the end of the year</td> <td valign="top" bgcolor="#CFF0FC" style=" border-bottom:double 2.5pt transparent;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style=" border-bottom:double 2.5pt transparent;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style=" border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;"> $</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">274,000</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style=" border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;"> $</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">199,000</td> <td valign="bottom" bgcolor="#CFF0FC" style=" border-bottom:double 2.5pt transparent;">  </td> </tr> </table></div>  </div>

<div>   (9) Subsequent Event None</div>

<div> Principles of Consolidation.  The accompanying consolidated financial statements have been derived from the historical cost basis of the assets and liabilities, financial condition and cash flows of Presbia PLC and Presbia Ireland, Limited, both organized in Ireland, Presbia Investments, a wholly-owned subsidiary of Presbia PLC organized in the Cayman Islands, and Presbia Ireland, Limited’s subsidiaries, Presbia Deutchland GmbH, Presbia USA, Inc., and OPL, LLC. Presbia Deutchland GmbH is organized in Germany, and Presbia USA, Inc. and OPL, LLC are both entities organized in the United States, and include Presbia USA, Inc.’s subsidiaries, Visitome, Inc. and PresbiBio, LLC, both organized in the United States, and OPL, LLC’s direct and indirect subsidiaries, PIP Holdings, C.V and Presbia Cooperatief U.A., both organized in the Netherlands, and PresbiOptical LLC, organized in the United States (collectively, including Presbia PLC, the “Company”).  The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”).  The Company’s fiscal year ends on December 31. The entities presented in the consolidated financial statements have been under common control during the periods presented. All intercompany accounts have been eliminated in consolidation.</div>

<div> Basis of Presentation.  The accompanying unaudited consolidated financial statements as of June 30, 2018 and for the three and six months ended June 30, 2018 and 2017, respectively, have been prepared in accordance with United States generally accepted accounting principles (“U.S.GAAP”) for interim financial reporting, and with the instructions to Form 10-Q and Article 8 of Regulation S-X. The accompanying consolidated balance sheet at December 31, 2017 has been derived from the audited consolidated balance sheet at December 31, 2017, contained in the annual report on Form 10-K for the year ended December 31, 2017. These consolidated financial statements should be read in conjunction with the audited consolidated financial statements presented in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2017, filed with the Securities and Exchange Commission on March 30, 2018. In the opinion of management, the accompanying consolidated financial statements reflect all adjustments which are necessary for a fair presentation of the results of operations and cash flows for the periods presented. The results of operations for such interim periods are not necessarily indicative of results of operations to be expected for the full year. References to amounts in the consolidated financial statement sections are in thousands, except per share data, unless otherwise specified.</div>

<div> Revenue Recognition Prior to 2018, we recognized revenue when there is persuasive evidence that an arrangement exists with our customers, selling prices are fixed or determinable, title or risk of loss has passed, and collection is reasonably assured. Revenue was recognized upon shipment and payments are either received in advance, or net 30 days for lenses or net 14 days for accessories. Distributor arrangements included certain perfunctory acceptance provisions and a one-year warranty, from the date of shipment, that products are free from defects in material workmanship. Under such provisions customers may reject shipments via written notifications ranging from 14-45 days or exchange defective product under warranty for the same non-defective product. We have not had any significant rejected shipments or warranty claims. We did not grant price concessions to our distributors.   In 2012, we changed our commercialization strategy from exclusively using distributors to also targeting refractive laser centers equipped with femtosecond lasers, except in countries that require the use of distributors or sales representatives. In December 2017, in light our re-ordering of operational priorities, we have focused our commercialization and clinical trial efforts outside of the U.S. in Germany and South Korea, including established ophthalmic clinics in those countries.  We recognize revenue from laser centers and ophthalmic clinics based upon an analysis of the terms of each customer arrangement and upon determination that persuasive evidence of an arrangement exists, selling prices are fixed or determinable, title or risk of loss has passed, and collection is reasonably assured. Revenues from laser centers and ophthalmic clinics during the three and six months ended June 30, 2018 and 2017 were not material.   Effective January 1, 2018, the Company adopted the provisions of Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 606, Revenue from Contracts with Customers (“ASC 606”), using the modified retrospective transition method. Under this method, the Company recognizes revenue based on an analysis of the goods and services provided to our customers in the ordinary course. We analyze all commercial agreements to identify (i) contracts and arrangements with customers that meet the criteria for revenue recognition under the new standard (ii) identify all performance obligations under the contractual arrangement, such as the delivery of our Microlens to our customers and any other deliverable(s) as defined in a commercial arrangement (iii) the determination of the transaction price and the allocation of such pricing over the defined contractual obligations in the contract with the customer and (iv) the recognition of revenue once the customer has assumed control over the contractual obligations. Control refers to the ability on the part of the customer to obtain substantially all the benefits of possession of the delivered product or service. </div>

<div> Comprehensive Loss Comprehensive income or loss is defined as a change in equity of a company attributable to all transactions excluding those transactions resulting from investment with owners and distributions to owners. There were no differences between net loss and comprehensive loss in the three and six months ended June 30, 2018 and 2017.</div>

<div> Future Accounting Pronouncements In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842).  The new standard requires lessees to recognize most leases on their balance sheets as lease liabilities with corresponding right-of-use assets and eliminates certain real estate-specific provisions.  ASU 2016-02 will be effective for the Company in the first quarter of 2019.  ASU 2016-02 will be adopted on a modified retrospective transition basis for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements. Although the Company is currently evaluating the full impact of ASU 2016-02 on its consolidated financial statements, upon adoption of ASU 2016-02 the Company anticipates that its operating leases will be recognized on the balance sheet as a lease liability if certain criteria is met, with a corresponding right of use asset. In February 2018, the FASB issued ASU 2018-02, Income Statement—Reporting Comprehensive Income (Topic 220)—Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income. This update was issued to address the income tax accounting treatment of the stranded tax effects within other comprehensive income due to the prohibition of backward tracing due to an income tax rate change that was initially recorded in other comprehensive income. This issue came about from the enactment of the Tax Cuts and Jobs Act on December 22, 2017, which changed the Company’s income tax rate from 35% to 21%. The ASU changed current accounting whereby an entity may elect to reclassify the stranded tax effect from accumulated other comprehensive income to retained earnings. The ASU is effective for periods beginning after December 15, 2018, although early adoption is permitted. The Company does not anticipate that the adoption of this ASU will have a material impact on its consolidated financial statements. In June 2018, the FASB issued ASU No. 2018-07, Compensation — Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting. The new standard expands the scope of Topic 718 to include all share-based payment transactions for acquiring goods and services from nonemployees. ASU No. 2018-07 specifies that Topic 718 applies to all share-based payment transactions in which the grantor acquires goods and services to be used or consumed in its own operations by issuing share-based payment awards. ASU NO. 2018-07 also clarifies that Topic 718 does not apply to share-based payments used to effectively provide (1) financing to the issuer or (2) awards granted in conjunction with selling goods or services to customers as part of a contract accounted for under ASC 606. ASU No. 2018-07 will be effective for the Company beginning after December 15, 2019, with early adoption permitted, but no earlier than the Company’s adoption of ASC 606. The Company is currently assessing the potential impact of adopting this guidance on its consolidated financial statements.</div>

<div> Recent Accounting Standards In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606).  The new standard is based on the principle that revenue should be recognized to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services.  ASU 2014-09 became effective for the Company in the first quarter of 2018 and allowed for full retrospective or a modified retrospective adoption approach. The Company adopted this new standard in January 2018 and it did not have a material adjustment on its consolidated financial statements. In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows, which clarifies the classification of certain cash receipts and payments.  The specific cash flow issues addressed by ASU 2016-15, with the objective of reducing the existing diversity in practice, are as follows: (1) Debt prepayment or debt extinguishment costs; (2) Settlement of zero-coupon debt instruments or other debt instruments with insignificant coupon interest rates; (3) Contingent consideration payments made after a business combination; (4) Proceeds from the settlement of insurance claims; (5) Proceeds from the settlement of corporate-owned life insurance policies; (6) Distributions received from equity method investees; (7) Beneficial interest in securitization transactions; and (8) Separately identifiable cash flows and application of the predominance in principle.  ASU 2016-15 became effective for fiscal years beginning after December 15, 2017.  The Company adopted this new standard in January 2018 and it did not have a material impact on its consolidated financial statements. <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In October 2016, the FASB issued ASU. 2016-16, Income Taxes (Topic 740): Intra-Entity Transfers of Assets Other than Inventory. This update requires entities to recognize the income tax consequences of an intra-entity transfer of an asset other than inventory when the transfer occurs. This update is effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. Early adoption is permitted as of the beginning of a fiscal year. The new standard must be adopted using a modified retrospective transition method, which is a cumulative-effective adjustment to retained earnings as of the beginning of the first effective reporting period. The Company adopted this new standard in January 2018 and it did not have a material impact on its consolidated financial statements. <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2017, the FASB issued ASU 2017-09, Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting, which provides guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. This update is effective for annual reporting periods beginning after December 15, 2017. Early adoption is permitted. The Company adopted this ASU in January 2018 and it did not have a material impact on its consolidated financial statements. </div>

<div> Basic and diluted loss per share for the three and six months ended June 30, 2018 and 2017 were calculated as follows:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:79.68%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.14%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.24%; border-bottom:solid 0.75pt transparent;">  </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.72%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Three-Months Ended June 30,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.24%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.74%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Six-Months Ended June 30,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.14%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.24%; border-bottom:solid 0.75pt transparent;">  </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2018</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2017</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.24%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2018</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.24%; border-top:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2017</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.14%;"> Net Loss</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.24%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%; border-top:solid 0.75pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.8%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,251</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;white-space:nowrap;"> )</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.24%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%; border-top:solid 0.75pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.8%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,533</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;white-space:nowrap;"> )</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.24%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%; border-top:solid 0.75pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.8%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,265</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;white-space:nowrap;"> )</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.24%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%; border-top:solid 0.75pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.8%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(9,125</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;white-space:nowrap;"> )</td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.14%;"> Weighted average shares outstanding    - basic and diluted</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.24%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.8%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,079,548</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.24%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.8%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,956,056</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.24%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.8%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,042,358</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.24%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.8%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,618,001</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.14%;"> Net loss per ordinary share    - basic and diluted</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.24%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.8%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.13</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;white-space:nowrap;"> )</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.24%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.8%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.27</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;white-space:nowrap;"> )</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.24%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.8%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.25</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;white-space:nowrap;"> )</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.24%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.8%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.58</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;white-space:nowrap;"> )</td> </tr> </table></div>  </div>

<div> The following table shows share-based compensation expense based upon all equity awards issued by Presbia PLC included in the Consolidated Statements of Operations for the three and six months ended June 30, 2018 and 2017. The Company recorded a credit of $86,000 and $524,000 as a result of the reversal of stock-based compensation for participants whose relationship with the Company terminated in the three and six months ended June 30, 2018, respectively.     <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.52%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">  </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.62%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Three-Months Ended June 30,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">  </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.62%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Six-Months Ended June 30,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.52%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">  </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2018</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2017</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%;">  </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2018</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-top:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2017</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.52%;"> Research and development</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(49</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> )</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">126</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(227</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> )</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">242</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.52%;"> General and administrative</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">174</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">311</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">175</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">641</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.52%; border-bottom:solid 0.75pt transparent;"> Sales and marketing</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">78</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">155</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.52%; border-bottom:double 2.5pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">155</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">515</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,038</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">  </td> </tr> </table></div>  </div>

<div> The following table sets forth the Company’s option activity for the six months ended June 30, 2018:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.36%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.9%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.3%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Number of <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Presbia PLC <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Shares</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.9%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.3%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Weighted Average <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Exercise Price <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Per Share</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.9%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.3%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Aggregate <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic Value</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.36%;"> Balance, January 1, 2018</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.3%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">849,100</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.3%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.77</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.3%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.36%;"> Granted</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.3%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">365,000</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> $ </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.3%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.38</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.3%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.36%;"> Exercised</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.3%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.3%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.3%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.36%; border-bottom:solid 0.75pt transparent;"> Forfeited/cancelled/expired</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.9%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(71,450</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> )</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.9%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.38</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.9%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:15.3%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.36%; border-bottom:double 2.5pt transparent;"> Balance, June 30, 2018</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.9%; border-bottom:double 2.5pt transparent;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,142,650</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.9%; border-bottom:double 2.5pt transparent;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.44</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.9%; border-bottom:double 2.5pt transparent;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:15.3%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.36%;"> Vested, June 30, 2018</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.3%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">726,150</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.3%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.82</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.3%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.36%;"> Non Vested, June 30, 2018</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.3%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">416,500</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.3%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.27</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.3%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.36%;"> Exercisable, June 30, 2018</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.3%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">726,150</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.3%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.82</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.3%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> </tr> </table></div>  </div>

<div> During the three and six months ended June 30, 2018 and 2017, the Company did not grant options to non-employee consultants and medical advisors. In contrast to the determination of the fair value of options granted to employees, which are determined based upon the grant-date assumptions and applying the Black-Scholes model, the fair values for non-employee options and the related stock-based compensation expense are remeasured each financial reporting period based upon the assumptions applicable on the dates in which the financial statements are prepared, which are disclosed in the following table:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80.76%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.48%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">  </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.22%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Three-Months Ended June 30,</td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;">  </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">  </td> <td colspan="7" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.66%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Six-Months Ended June 30,</td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:28.48%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">  </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.76%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2018</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.74%;">  </td> <td colspan="3" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.9%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2017</td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">  </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.26%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2018</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%;">  </td> <td colspan="3" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.86%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">2017</td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock price per share</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.76%; border-top:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$0.85 - $1.13</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.74%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="3" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.9%; border-top:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$1.25 - $1.63</td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.26%; border-top:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$0.85 - $1.95</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="3" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.86%; border-top:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$1.25 - $2.51</td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.76%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.6 - 7.1 Yrs.</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.74%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="3" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.9%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.7 - 8.4 Yrs</td> <td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.26%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.6 - 7.4 Yrs.</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="3" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.86%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.7 - 8.6 Yrs</td> <td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Volatility</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.76%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72.9% - 77.3%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.74%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="3" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.9%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">79.1% - 83.5%</td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.26%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72.9% - 77.3%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="3" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.86%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">79.1% - 90.0%</td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dividends</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.74%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.36%;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.96%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free rate</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.76%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.8%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.74%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="3" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.9%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.2%</td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.26%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.6% - 2.8%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="3" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.86%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.2% - 2.3%</td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%;white-space:nowrap;">  </td> </tr> </table></div>  </div>

<div> The Company awarded 23,255 ordinary shares to the head of the Company’s medical advisory board as compensation for services provided during the six-month period ended June 30, 2018. The number of shares was determined by the closing price of $2.15 on June 29, 2018. The following table sets forth the Company’s restricted share activity for the three and six months ended June 30, 2018:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.72%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.5%; border-bottom:solid 0.75pt transparent;">  </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.62%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Unvested Number of <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Shares</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.5%; border-bottom:solid 0.75pt transparent;">  </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.62%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Weighted Average Fair <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Value per Share</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.72%;"> Balance, December 31, 2017</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.5%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.62%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">134,367</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.5%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.62%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.78</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.72%;"> Granted</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.5%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.62%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,255</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.5%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.62%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.15</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.72%;"> Vested</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.5%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.62%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(104,731</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> )</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.5%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.62%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.02</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.72%; border-bottom:solid 0.75pt transparent;"> Forfeited/cancelled</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.5%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.62%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.5%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.62%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.72%; border-bottom:double 2.5pt transparent;"> Unvested, June 30, 2018</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.5%; border-bottom:double 2.5pt transparent;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.62%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52,891</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.5%; border-bottom:double 2.5pt transparent;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.62%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.45</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">  </td> </tr> </table></div>  </div>

<div> The following table sets forth the Company’s RSU activity for the six months ended June 30, 2018:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.42%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.36%; border-bottom:solid 0.75pt transparent;">  </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.4%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Unvested Number of <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Shares</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.36%; border-bottom:solid 0.75pt transparent;">  </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.4%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Weighted Average Fair <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Value per Share</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.42%;"> Balance, December 31, 2017</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.4%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">739,000</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.4%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.09</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.42%;"> Granted</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.4%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.4%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.42%;"> Vested</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.4%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.4%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.42%; border-bottom:solid 0.75pt transparent;"> Forfeited/cancelled</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.36%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.4%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(226,000</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> )</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.36%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.4%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.44</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.42%; border-bottom:double 2.5pt transparent;"> Unvested, June 30, 2018</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.36%; border-bottom:double 2.5pt transparent;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.4%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">513,000</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.36%; border-bottom:double 2.5pt transparent;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.4%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.32</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">  </td> </tr> </table></div>  </div>

<div> A reconciliation of gross unrecognized tax benefits is as follows:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:76.19%;"> <tr> <td style="width:41.67%;"></td> <td style="width:0.19%;"></td> <td style="width:0.06%;"></td> <td style="width:1.06%;"></td> <td style="width:13.52%;"></td> <td style="width:2.21%;"></td> <td style="width:1.06%;"></td> <td style="width:15.6%;"></td> <td style="width:0.84%;"></td> </tr> <tr style="height:1pt;"> <td valign="bottom" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;white-space:nowrap;">  </td> <td valign="top">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td colspan="4" valign="bottom">  </td> </tr> <tr style="height:1pt;"> <td valign="bottom" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> <td valign="top" style=" border-bottom:solid 0.75pt transparent;">  </td> <td valign="top" style=" border-bottom:solid 0.75pt transparent;">  </td> <td valign="top" style=" border-bottom:solid 0.75pt #000000;">  </td> <td valign="bottom" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">June 30, 2018</td> <td valign="bottom" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> <td valign="top" style=" border-bottom:solid 0.75pt #000000;">  </td> <td valign="bottom" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2017</td> </tr> <tr style="height:1pt;"> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;white-space:nowrap;"> Balance at the beginning of the year</td> <td valign="top" bgcolor="#CFF0FC">  </td> <td valign="top" bgcolor="#CFF0FC">  </td> <td valign="top" bgcolor="#CFF0FC" style=" border-top:solid 0.75pt #000000;">  </td> <td valign="top" bgcolor="#CFF0FC" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">199,000</td> <td valign="top" bgcolor="#CFF0FC" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;white-space:nowrap;">  </td> <td valign="top" bgcolor="#CFF0FC">  </td> <td valign="top" bgcolor="#CFF0FC" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC">  </td> </tr> <tr style="height:1pt;"> <td valign="bottom" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> Increases related to current year tax positions</td> <td valign="top" style=" border-bottom:solid 0.75pt transparent;">  </td> <td valign="top" style=" border-bottom:solid 0.75pt transparent;">  </td> <td valign="top" style=" border-bottom:solid 0.75pt #000000;">  </td> <td valign="bottom" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75,000</td> <td valign="bottom" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> <td valign="top" style=" border-bottom:solid 0.75pt #000000;">  </td> <td valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">199,000</td> <td valign="bottom" style=" border-bottom:solid 0.75pt transparent;">  </td> </tr> <tr style="height:1pt;"> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;white-space:nowrap;"> Balance at the end of the year</td> <td valign="top" bgcolor="#CFF0FC" style=" border-bottom:double 2.5pt transparent;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style=" border-bottom:double 2.5pt transparent;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style=" border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;"> $</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">274,000</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt; border-bottom:double 2.5pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style=" border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;"> $</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">199,000</td> <td valign="bottom" bgcolor="#CFF0FC" style=" border-bottom:double 2.5pt transparent;">  </td> </tr> </table></div>  </div>

P30D P14D P1Y P14D P45D

28000

-52000

-24000

-79000

0.35

0.21

1049795

1152500

972019

1050000

P5Y

2200000

367591

P10Y

2025-01-14

0.20

86000 524000

-49000

126000

-227000

242000

174000

311000

175000

641000

30000

78000

60000

155000

515000

8000

1038000

849100

365000

71450

1142650

726150

416500

726150

9.77

2.38

9.38

7.44

9.82 3.27

9.82

365000

0.20

P5Y

P6Y9M

0.85 1.13 1.25 1.63 0.85 1.95 1.25 2.51

P6Y7M6D

P7Y1M6D

P7Y8M12D

P8Y4M24D

P6Y7M6D

P7Y4M24D

P7Y8M12D

P8Y7M6D

0.729

0.791

0.729

0.791

0.773

0.835

0.773

0.900

0.028

0.022

0.026

0.028

0.022

0.023

23255

2.15

134367

23255

104731

52891

3.78

2.15

3.02

5.45

0.20 P20D 10.00 15.00 20.00 25.00 30.00

P1Y

P7Y

739000

226000

513000

2.09

2.44

1.32

785000

2740000

P1Y9M18D

P1Y6M

P2Y3M18D

P1Y8M12D

P10M24D

P2Y4M24D

226000

290000

513000

7710000

250000

P5Y 2017-01

1.00

An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained.

274000

199000

35000

39000

199000

75000

274000

199000

100

4900

5000000

1953125

2.56

P5Y

0.10

0.20

0.30

50334

8000000 1000000 1000000

P5Y

2017-05-31

P5Y

2022-05-31

P1Y

P1M

2013-12-01

P30M

2018-02 2016-01-01 1 222000 P33M

113000

168000

208000

337000

EX-101.SCH 6 lens-20180630.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000 - Document - Template Link link:presentationLink link:calculationLink link:definitionLink 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink 100010 - Statement - Condensed Consolidated Balance Sheets link:calculationLink link:presentationLink link:definitionLink 100020 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 100030 - Statement - Condensed Consolidated Statements of Operations (Unaudited) link:calculationLink link:presentationLink link:definitionLink 100040 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:calculationLink link:presentationLink link:definitionLink 100050 - Disclosure - Basis of Presentation link:calculationLink link:presentationLink link:definitionLink 100060 - Disclosure - Summary of Significant Accounting Policies link:calculationLink link:presentationLink link:definitionLink 100070 - Disclosure - Loss per Share link:calculationLink link:presentationLink link:definitionLink 100080 - Disclosure - Equity Based Awards link:calculationLink link:presentationLink link:definitionLink 100090 - Disclosure - Concentration of Credit Risk link:calculationLink link:presentationLink link:definitionLink 100100 - Disclosure - Income Taxes link:calculationLink link:presentationLink link:definitionLink 100110 - Disclosure - Equity Transaction with Related Party link:calculationLink link:presentationLink link:definitionLink 100120 - Disclosure - Commitments and Contingencies link:calculationLink link:presentationLink link:definitionLink 100130 - Disclosure - Subsequent Event link:calculationLink link:presentationLink link:definitionLink 100140 - Disclosure - Basis of Presentation (Policies) link:calculationLink link:presentationLink link:definitionLink 100150 - Disclosure - Loss per Share (Tables) link:calculationLink link:presentationLink link:definitionLink 100160 - Disclosure - Equity Based Awards (Tables) link:calculationLink link:presentationLink link:definitionLink 100170 - Disclosure - Income Taxes (Tables) link:calculationLink link:presentationLink link:definitionLink 100180 - Disclosure - Basis of Presentation - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100190 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100200 - Disclosure - Loss per Share - Schedule of Calculation of Basic and Diluted Loss per Share (Detail) link:calculationLink link:presentationLink link:definitionLink 100210 - Disclosure - Loss per Share - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100220 - Disclosure - Equity Based Awards - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100230 - Disclosure - Equity Based Awards - Share-Based Compensation Expense Included in Consolidated Statements of Operations (Detail) link:calculationLink link:presentationLink link:definitionLink 100240 - Disclosure - Equity Based Awards - Schedule of Option Activity (Detail) link:calculationLink link:presentationLink link:definitionLink 100250 - Disclosure - Equity Based Awards - Schedule of Black-Scholes Valuation Model Assumptions for Estimating the Fair Value of Share-Based Compensation (Detail) link:calculationLink link:presentationLink link:definitionLink 100260 - Disclosure - Equity Based Awards - Schedule of Restricted Share Activity (Detail) link:calculationLink link:presentationLink link:definitionLink 100270 - Disclosure - Equity Based Awards - Schedule of RSU Activity (Detail) link:calculationLink link:presentationLink link:definitionLink 100280 - Disclosure - Concentration of Credit Risk - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100290 - Disclosure - Income Taxes - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100300 - Disclosure - Income Taxes - Schedule of Reconciliation of Gross Unrecognized Tax Benefits (Detail) link:calculationLink link:presentationLink link:definitionLink 100310 - Disclosure - Equity Transaction with Related Party - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100320 - Disclosure - Commitments and Contingencies - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink EX-101.CAL 7 lens-20180630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 8 lens-20180630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 9 lens-20180630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity Central Index Key Document And Entity Information [Abstract] Document And Entity Information [Abstract] Document Type Document Type Amendment Flag Amendment Flag Document Period End Date Document Period End Date Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Trading Symbol Trading Symbol Entity Registrant Name Entity Registrant Name Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Entity Filer Category Entity Filer Category Entity Common Stock, Shares Outstanding Entity Common Stock Shares Outstanding Deferred ordinary shares value. Statement Of Financial Position [Abstract] Statement [Table] Statement [Table] Class of Stock Statement Class Of Stock [Axis] Class of Stock Class Of Stock [Domain] Series A Redeemable Preferred Shares [Member] Series A Preferred Stock [Member] USA Preferred shares. USA Preferred Shares [Member] U S A Preferred Shares [Member] Statement [Line Items] Statement [Line Items] Assets Assets [Abstract] Current assets Assets Current [Abstract] Cash Cash Accounts receivable Accounts Receivable Net Current Inventory, net Inventory Net Prepaid expenses and other current assets Prepaid Expense And Other Assets Current Total current assets Assets Current Property and equipment, net Property Plant And Equipment Net Intangible asset Finite Lived Intangible Assets Net Other assets Other Assets Noncurrent Total assets Assets Liabilities and shareholders’ equity Liabilities And Stockholders Equity [Abstract] Current liabilities Liabilities Current [Abstract] Accounts payable Accounts Payable Current Due to related parties Due To Related Parties Current Note payable, current portion Notes Payable Current Other current liabilities Other Liabilities Current Total current liabilities Liabilities Current Deferred rent Deferred Rent Credit Noncurrent Due to related parties, net of current portion Due To Related Parties Noncurrent Other liabilities, net of current portion Other Liabilities Noncurrent Total liabilities Liabilities Commitments and contingencies (note 7) Commitments And Contingencies Shareholders' equity Stockholders Equity [Abstract] Preferred shares Preferred Stock Value Ordinary Shares $0.001 par value, 350,000,000 shares authorized; 17,157,160 and 17,121,857 shares issued and outstanding at June 30, 2018 and December 31, 2017 Common Stock Value Deferred ordinary Shares €1.00 (US$1.35) par value, 39,994 shares authorized, issued and outstanding at June 30, 2018 and December 31, 2017 Deferred Ordinary Shares Value Additional paid-in capital Additional Paid In Capital Common Stock Accumulated deficit Retained Earnings Accumulated Deficit Total shareholders' equity Stockholders Equity Total liabilities and shareholders’ equity Liabilities And Stockholders Equity Deferred ordinary shares par or stated value per share. Deferred ordinary shares authorized. Deferred ordinary shares issued. Deferred ordinary shares outstanding. Preferred shares, par value Preferred Stock Par Or Stated Value Per Share Preferred shares, shares authorized Preferred Stock Shares Authorized Preferred shares, shares issued Preferred Stock Shares Issued Preferred shares, shares outstanding Preferred Stock Shares Outstanding Ordinary shares, par value Common Stock Par Or Stated Value Per Share Ordinary shares, shares authorized Common Stock Shares Authorized Ordinary shares, shares issued Common Stock Shares Issued Ordinary shares, shares outstanding Common Stock Shares Outstanding Deferred ordinary shares, par value Deferred Ordinary Shares Par Or Stated Value Per Share Deferred ordinary shares, shares authorized Deferred Ordinary Shares Authorized Deferred ordinary shares, shares issued Deferred Ordinary Shares Issued Deferred ordinary shares, shares outstanding Deferred Ordinary Shares Outstanding Income Statement [Abstract] Revenues Revenue From Contract With Customer Excluding Assessed Tax Type of Revenue [Extensible List] Type Of Revenue Extensible List Cost of goods sold Cost Of Goods And Services Sold Type of Cost, Good or Service [Extensible List] Type Of Cost Good Or Service Extensible List Gross profit (loss) Gross Profit Operating expenses: Operating Expenses [Abstract] Research and development Research And Development Expense Sales and marketing Selling And Marketing Expense General and administrative General And Administrative Expense Total operating expenses Operating Expenses Operating loss Operating Income Loss Other expense Other Nonoperating Income Expense Interest expense Interest Income Expense Nonoperating Net Loss before income tax provision Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest Income tax provision Income Tax Expense Benefit Net loss Net Income Loss Net loss per ordinary share-basic and diluted Earnings Per Share Basic And Diluted Weighted average shares outstanding - basic and diluted Weighted Average Number Of Share Outstanding Basic And Diluted Imputed interest expense. Statement Of Cash Flows [Abstract] Cash flow from operating activities: Net Cash Provided By Used In Operating Activities Continuing Operations [Abstract] Net loss Profit Loss Adjustments to reconcile net loss to net cash used in operating activities: Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract] Depreciation and amortization Depreciation Depletion And Amortization Inventory provisions Inventory Write Down Stock-based compensation Share Based Compensation Loss on disposition of fixed assets Gain Loss On Disposition Of Assets1 Imputed interest expense Imputed Interest Expense Changes in operating assets and liabilities: Increase Decrease In Operating Capital [Abstract] Accounts receivable Increase Decrease In Accounts Receivable Inventory Increase Decrease In Inventories Prepaid expenses and other current assets Increase Decrease In Prepaid Deferred Expense And Other Assets Other assets Increase Decrease In Other Operating Assets Accounts payable and other current liabilities Increase Decrease In Accounts Payable And Other Operating Liabilities Income taxes payable Increase Decrease In Accrued Income Taxes Payable Deferred rent Increase Decrease In Deferred Liabilities Due to related parties Increase Decrease In Due To Related Parties Net cash used in operating activities Net Cash Provided By Used In Operating Activities Cash flow from investing activities: Net Cash Provided By Used In Investing Activities [Abstract] Purchases of intangible assets Payments To Acquire Intangible Assets Purchases of property and equipment Payments To Acquire Property Plant And Equipment Net cash used in investing activities Net Cash Provided By Used In Investing Activities Cash flow from financing activities: Net Cash Provided By Used In Financing Activities [Abstract] Proceeds from issuance of ordinary shares from rights offering, net of costs Proceeds From Issuance Of Common Stock Proceeds from issuance of preferred shares, net of costs Proceeds From Issuance Of Preferred Stock And Preference Stock Net cash provided by financing activities Net Cash Provided By Used In Financing Activities Net increase in cash Cash Period Increase Decrease Excluding Exchange Rate Effect Effect of exchange rate on cash Effect Of Exchange Rate On Cash Cash balance at beginning of period Cash balance at end of period Accounting Policies [Abstract] Basis of Presentation Business Description And Basis Of Presentation [Text Block] Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Earnings Per Share [Abstract] Loss per Share Earnings Per Share [Text Block] Disclosure Of Compensation Related Costs Sharebased Payments [Abstract] Equity Based Awards Disclosure Of Compensation Related Costs Share Based Payments [Text Block] Risks And Uncertainties [Abstract] Concentration of Credit Risk Concentration Risk Disclosure [Text Block] Income Tax Disclosure [Abstract] Income Taxes Income Tax Disclosure [Text Block] Class Of Stock Disclosures [Abstract] Equity Transaction with Related Party Related Party Transactions Disclosure [Text Block] Commitments And Contingencies Disclosure [Abstract] Commitments and Contingencies Commitments And Contingencies Disclosure [Text Block] Subsequent Events [Abstract] Subsequent Event Subsequent Events [Text Block] Principles of Consolidation Consolidation Policy [Text Block] Basis of Presentation Basis Of Accounting Policy Policy [Text Block] Liquidity. Liquidity Liquidity Policy [Text Block] Revenue Recognition Revenue Recognition Policy [Text Block] Foreign Currency Foreign Currency Transactions And Translations Policy [Text Block] Comprehensive Loss Comprehensive Income Policy Policy [Text Block] Future accounting pronouncements. Future Accounting Pronouncements Future Accounting Pronouncements Policy Policy [Text Block] Recent Accounting Standards New Accounting Pronouncements Policy Policy [Text Block] Schedule of Calculation of Basic and Diluted Loss per Share Schedule Of Earnings Per Share Basic And Diluted Table [Text Block] Award Type Award Type [Axis] Equity Award Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain] Non employee stock option. Non-employee options [Member] Non Employee Stock Option [Member] Share-Based Compensation Expense Included in Consolidated Statements of Operations Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block] Schedule of Option Activity Schedule Of Share Based Compensation Stock Options Activity Table [Text Block] Schedule of Black-Scholes Valuation Model Assumptions for Estimating the Fair Value of Share-Based Compensation Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block] Schedule of Restricted Shares Activity Nonvested Restricted Stock Shares Activity Table [Text Block] Schedule of RSU Activity Schedule Of Nonvested Restricted Stock Units Activity Table [Text Block] Schedule of Reconciliation of Gross Unrecognized Tax Benefits Schedule Of Unrecognized Tax Benefits Roll Forward Table [Text Block] Organization Consolidation And Presentation Of Financial Statements [Abstract] Accumulated deficit Payments collection period. Written notification period to reject shipments by customers. Waaranty period. Regulatory assets. Regulatory Assets [Abstract] Significant accounting policies. Significant accounting policies. Significant Accounting Policies [Table] Significant Accounting Policies [Table] Product and Service Product Or Service [Axis] Product and Service Products And Services [Domain] Lenses. Lenses [Member] Lenses [Member] Accessories. Accessories [Member] Accessories [Member] Range Range [Axis] Range Range [Member] Minimum [Member] Minimum [Member] Maximum [Member] Maximum [Member] Income Statement Location Income Statement Location [Axis] Income Statement Location Income Statement Location [Domain] General and Administrative Expense [Member] General And Administrative Expense [Member] Significant Accounting Policies [Line Items] Significant Accounting Policies [Line Items] Payments collection period Payments Collection Period Warranty period, from the date of shipment Waaranty Period Written notification period to reject shipments by customers Written Notification Period To Reject Shipments By Customers Aggregate foreign exchange gain (loss) Foreign Currency Transaction Gain Loss Before Tax Income tax rate Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate Basic and diluted net loss per share Earnings Per Share Basic And Diluted [Abstract] Net Loss Weighted average shares outstanding - basic and diluted Net loss per ordinary share - basic and diluted Antidilutive securities, not included in diluted net loss per calculation Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table] Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table] Plan Name Plan Name [Axis] Plan Name Plan Name [Domain] Presbia incentive plan. Presbia Incentive Plan [Member] Presbia Incentive Plan [Member] Vesting Vesting [Axis] Vesting Vesting [Domain] Over five year period. Over five year period [Member] Over Five Year Period [Member] Employee Options [Member] Employee Stock Option [Member] Title of Individual Title Of Individual [Axis] Relationship to Entity Title Of Individual With Relationship To Entity [Domain] Non-employee consultants and medical advisors. Non-employee consultants and medical advisors [Member] Non Employee Consultants And Medical Advisors [Member] Medical advisory board compensation. Medical Advisory Board Compensation [Member] Medical Advisory Board Compensation [Member] Threshold Price Period 1 [Member] Share Based Compensation Award Tranche One [Member] Threshold Price Period 2 [Member] Share Based Compensation Award Tranche Two [Member] Threshold Price Period 3 [Member] Share Based Compensation Award Tranche Three [Member] share based compensation award tranche four member. Threshold Price Period 4 [Member] Share Based Compensation Award Tranche Four [Member] Share based compensation award tranche five member. Threshold Price Period 5 [Member] Share Based Compensation Award Tranche Five [Member] Restricted Share Units [Member] Restricted Stock Units R S U [Member] Restricted shares [Member] Restricted Stock [Member] Employee and non employee. Employee and non-employee options [Member] Employee And Non Employee [Member] Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Awards vesting period Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 Ordinary shares authorized for issuance Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized Ordinary shares available for future grants and awards Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant EX-101.PRE 10 lens-20180630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 11 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	6 Months Ended
Document and Entity Information - shares	Jun. 30, 2018	Aug. 10, 2018
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2018
Document Fiscal Year Focus	2018
Document Fiscal Period Focus	Q2
Trading Symbol	LENS
Entity Registrant Name	PRESBIA PLC
Entity Central Index Key	0001591096
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		17,157,160

XML 12 R2.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017
Current assets
Cash	$ 3,328	$ 3,236
Accounts receivable	23	8
Inventory, net	71	127
Prepaid expenses and other current assets	305	108
Total current assets	3,727	3,479
Property and equipment, net	410	477
Intangible asset	1,411	1,479
Other assets	77	127
Total assets	5,625	5,562
Current liabilities
Accounts payable	471	628
Due to related parties	35	23
Note payable, current portion	482	480
Other current liabilities	744	1,151
Total current liabilities	1,732	2,282
Deferred rent	98	107
Due to related parties, net of current portion		12
Other liabilities, net of current portion	25	30
Total liabilities	1,855	2,431
Commitments and contingencies (note 7)
Shareholders' equity
Ordinary Shares $0.001 par value, 350,000,000 shares authorized; 17,157,160 and 17,121,857 shares issued and outstanding at June 30, 2018 and December 31, 2017	17	17
Deferred ordinary Shares €1.00 (US$1.35) par value, 39,994 shares authorized, issued and outstanding at June 30, 2018 and December 31, 2017	54	54
Additional paid-in capital	96,266	91,362
Accumulated deficit	(92,567)	(88,302)
Total shareholders' equity	3,770	3,131
Total liabilities and shareholders’ equity	5,625	5,562
Series A Redeemable Preferred Shares [Member]
Shareholders' equity
Preferred shares
USA Preferred Shares [Member]
Shareholders' equity
Preferred shares

XML 13 R3.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Parenthetical)	Jun. 30, 2018 $ / shares shares	Jun. 30, 2018 € / shares shares	Dec. 31, 2017 $ / shares shares	Dec. 31, 2017 € / shares shares
Ordinary shares, par value \| $ / shares	$ 0.001		$ 0.001
Ordinary shares, shares authorized	350,000,000	350,000,000	350,000,000	350,000,000
Ordinary shares, shares issued	17,157,160	17,157,160	17,157,160	17,157,160
Ordinary shares, shares outstanding	17,121,857	17,121,857	17,121,857	17,121,857
Deferred ordinary shares, par value \| (per share)	$ 1.35	€ 1.00	$ 1.35	€ 1.00
Deferred ordinary shares, shares authorized	39,994	39,994	39,994	39,994
Deferred ordinary shares, shares issued	39,994	39,994	39,994	39,994
Deferred ordinary shares, shares outstanding	39,994	39,994	39,994	39,994
Series A Redeemable Preferred Shares [Member]
Preferred shares, par value \| $ / shares	$ 0.001		$ 0.001
Preferred shares, shares authorized	50,000,000	50,000,000	50,000,000	50,000,000
Preferred shares, shares issued	100	100	0	0
Preferred shares, shares outstanding	100	100	0	0
USA Preferred Shares [Member]
Preferred shares, par value \| $ / shares	$ 0.01		$ 0.01
Preferred shares, shares authorized	8,000	8,000	8,000	8,000
Preferred shares, shares issued	4,900	4,900	0	0
Preferred shares, shares outstanding	4,900	4,900	0	0

XML 14 R4.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Income Statement [Abstract]
Revenues	$ 3		$ 7	$ 5
Type of Revenue [Extensible List]	us-gaap:ProductMember	us-gaap:ProductMember	us-gaap:ProductMember	us-gaap:ProductMember
Cost of goods sold	$ 1	$ 17	$ 48	$ 28
Type of Cost, Good or Service [Extensible List]	us-gaap:ProductMember	us-gaap:ProductMember	us-gaap:ProductMember	us-gaap:ProductMember
Gross profit (loss)	$ 2	$ (17)	$ (41)	$ (23)
Operating expenses:
Research and development	974	2,022	1,684	3,863
Sales and marketing	360	816	712	1,777
General and administrative	894	1,649	1,756	3,403
Total operating expenses	2,228	4,487	4,152	9,043
Operating loss	(2,226)	(4,504)	(4,193)	(9,066)
Other expense	(10)		(10)
Interest expense	(10)	(4)	(19)	(18)
Loss before income tax provision	(2,246)	(4,508)	(4,222)	(9,084)
Income tax provision	5	25	43	41
Net loss	$ (2,251)	$ (4,533)	$ (4,265)	$ (9,125)
Net loss per ordinary share-basic and diluted	$ (0.13)	$ (0.27)	$ (0.25)	$ (0.58)
Weighted average shares outstanding - basic and diluted	17,079,548	16,956,056	17,042,358	15,618,001

XML 15 R5.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
Cash flow from operating activities:
Net loss	$ (4,265)	$ (9,125)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	126	171
Inventory provisions	45	29
Stock-based compensation	8	1,038
Loss on disposition of fixed assets	9
Imputed interest expense	21	40
Changes in operating assets and liabilities:
Accounts receivable	(15)	(7)
Inventory	11	24
Prepaid expenses and other current assets	(196)	(100)
Other assets	50	(2)
Accounts payable and other current liabilities	(747)	698
Income taxes payable	69	39
Deferred rent	(9)	58
Due to related parties	12	10
Net cash used in operating activities	(4,881)	(7,127)
Cash flow from investing activities:
Purchases of intangible assets	(2)	(87)
Purchases of property and equipment		(7)
Net cash used in investing activities	(2)	(94)
Cash flow from financing activities:
Proceeds from issuance of ordinary shares from rights offering, net of costs		10,485
Proceeds from issuance of preferred shares, net of costs	4,994
Net cash provided by financing activities	4,994	10,485
Net increase in cash	111	3,264
Effect of exchange rate on cash	(19)	71
Cash balance at beginning of period	3,236	7,333
Cash balance at end of period	$ 3,328	$ 10,668

XML 16 R6.htm IDEA: XBRL DOCUMENT

Basis of Presentation	6 Months Ended
Basis of Presentation	Jun. 30, 2018
Accounting Policies [Abstract]
Basis of Presentation	(1) Basis of Presentation Principles of Consolidation. The accompanying consolidated financial statements have been derived from the historical cost basis of the assets and liabilities, financial condition and cash flows of Presbia PLC and Presbia Ireland, Limited, both organized in Ireland, Presbia Investments, a wholly-owned subsidiary of Presbia PLC organized in the Cayman Islands, and Presbia Ireland, Limited’s subsidiaries, Presbia Deutchland GmbH, Presbia USA, Inc., and OPL, LLC. Presbia Deutchland GmbH is organized in Germany, and Presbia USA, Inc. and OPL, LLC are both entities organized in the United States, and include Presbia USA, Inc.’s subsidiaries, Visitome, Inc. and PresbiBio, LLC, both organized in the United States, and OPL, LLC’s direct and indirect subsidiaries, PIP Holdings, C.V and Presbia Cooperatief U.A., both organized in the Netherlands, and PresbiOptical LLC, organized in the United States (collectively, including Presbia PLC, the “Company”). The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). The Company’s fiscal year ends on December 31. The entities presented in the consolidated financial statements have been under common control during the periods presented. All intercompany accounts have been eliminated in consolidation. Basis of Presentation. The accompanying unaudited consolidated financial statements as of June 30, 2018 and for the three and six months ended June 30, 2018 and 2017, respectively, have been prepared in accordance with United States generally accepted accounting principles (“U.S.GAAP”) for interim financial reporting, and with the instructions to Form 10-Q and Article 8 of Regulation S-X. The accompanying consolidated balance sheet at December 31, 2017 has been derived from the audited consolidated balance sheet at December 31, 2017, contained in the annual report on Form 10-K for the year ended December 31, 2017. These consolidated financial statements should be read in conjunction with the audited consolidated financial statements presented in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2017, filed with the Securities and Exchange Commission on March 30, 2018. In the opinion of management, the accompanying consolidated financial statements reflect all adjustments which are necessary for a fair presentation of the results of operations and cash flows for the periods presented. The results of operations for such interim periods are not necessarily indicative of results of operations to be expected for the full year. References to amounts in the consolidated financial statement sections are in thousands, except per share data, unless otherwise specified. Liquidity At June 30, 2018, the Company has an accumulated deficit of $92.6 million and it expects to incur significant additional future operating losses. As it continues to incur losses, the Company’s transition to profitability will depend on the successful development, approval and commercialization of its microlens. The Company may never achieve profitability, and unless and until it does, it will need to continue to raise additional capital. Based on the Company’s current business plan, management believes that its cash and cash equivalents at June 30, 2018 will not be sufficient to meet its anticipated cash requirements during the twelve-month period subsequent to the issuance of the financial statements included in this Quarterly Report on Form 10-Q. These factors raise substantial doubt about the Company’s ability to continue as a going concern within one year from the date this Quarterly Report on Form 10-Q is filed with the U.S. Securities and Exchange Commission (SEC). The Company’s current commercialization strategy is targeted to countries where the Company can establish the market for its technology. This commercialization strategy will undergo continual prioritization and in the future the Company may adjust its commercialization efforts to preserve its existing cash or realize better results than anticipated which could have a positive impact on cash. The Company’s U.S. pivotal clinical trial and planned FDA approval is its highest priority. The Company must raise additional capital to fund its operations. It plans to raise additional capital through equity offerings, debt financings, collaborations and/or licensing arrangements. Additional funds may not be available when the Company needs them on terms that are acceptable to the Company, or at all. If adequate funds are not available on acceptable terms, the Company may be required to delay, reduce the scope of, or curtail, its operations. To the extent that the Company raises additional funds by issuing equity securities, its shareholders will experience dilution, and debt financing, if available, may involve restrictive covenants.

XML 17 R7.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies	6 Months Ended
Summary of Significant Accounting Policies	Jun. 30, 2018
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	(2) Summary of Significant Accounting Policies During the six months ended June 30, 2018 there have been no changes to the Company’s significant accounting policies as described in the Annual Report on Form 10-K for the fiscal year ended December 31, 2017, other than the adoption of the new revenue recognition standard noted below. Revenue Recognition Prior to 2018, we recognized revenue when there is persuasive evidence that an arrangement exists with our customers, selling prices are fixed or determinable, title or risk of loss has passed, and collection is reasonably assured. Revenue was recognized upon shipment and payments are either received in advance, or net 30 days for lenses or net 14 days for accessories. Distributor arrangements included certain perfunctory acceptance provisions and a one-year warranty, from the date of shipment, that products are free from defects in material workmanship. Under such provisions customers may reject shipments via written notifications ranging from 14-45 days or exchange defective product under warranty for the same non-defective product. We have not had any significant rejected shipments or warranty claims. We did not grant price concessions to our distributors. In 2012, we changed our commercialization strategy from exclusively using distributors to also targeting refractive laser centers equipped with femtosecond lasers, except in countries that require the use of distributors or sales representatives. In December 2017, in light our re-ordering of operational priorities, we have focused our commercialization and clinical trial efforts outside of the U.S. in Germany and South Korea, including established ophthalmic clinics in those countries. We recognize revenue from laser centers and ophthalmic clinics based upon an analysis of the terms of each customer arrangement and upon determination that persuasive evidence of an arrangement exists, selling prices are fixed or determinable, title or risk of loss has passed, and collection is reasonably assured. Revenues from laser centers and ophthalmic clinics during the three and six months ended June 30, 2018 and 2017 were not material. Effective January 1, 2018, the Company adopted the provisions of Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 606, Revenue from Contracts with Customers (“ASC 606”), using the modified retrospective transition method. Under this method, the Company recognizes revenue based on an analysis of the goods and services provided to our customers in the ordinary course. We analyze all commercial agreements to identify (i) contracts and arrangements with customers that meet the criteria for revenue recognition under the new standard (ii) identify all performance obligations under the contractual arrangement, such as the delivery of our Microlens to our customers and any other deliverable(s) as defined in a commercial arrangement (iii) the determination of the transaction price and the allocation of such pricing over the defined contractual obligations in the contract with the customer and (iv) the recognition of revenue once the customer has assumed control over the contractual obligations. Control refers to the ability on the part of the customer to obtain substantially all the benefits of possession of the delivered product or service. Foreign Currency The functional currency of subsidiaries outside the United States of America is the U.S. Dollar. Transactions in foreign currencies during the year are re-measured at rates of exchange on the dates of the transactions. Gains and losses related to re-measurement of items arising through operating activities are accounted for in the statement of operations and comprehensive loss and included in general and administrative expense. Aggregate foreign exchange gains and losses are included in the Condensed Consolidated Statement of Operations. Aggregate foreign exchange gain was $28,000 for the three months ended June 30, 2018, and aggregate foreign exchange loss was $24,000 for the six months ended June 30, 2018. Aggregate foreign exchange loss was $52,000 and $79,000 for the three and six months ended June 30, 2017, respectively. Comprehensive Loss Comprehensive income or loss is defined as a change in equity of a company attributable to all transactions excluding those transactions resulting from investment with owners and distributions to owners. There were no differences between net loss and comprehensive loss in the three and six months ended June 30, 2018 and 2017. Future Accounting Pronouncements In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). The new standard requires lessees to recognize most leases on their balance sheets as lease liabilities with corresponding right-of-use assets and eliminates certain real estate-specific provisions. ASU 2016-02 will be effective for the Company in the first quarter of 2019. ASU 2016-02 will be adopted on a modified retrospective transition basis for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements. Although the Company is currently evaluating the full impact of ASU 2016-02 on its consolidated financial statements, upon adoption of ASU 2016-02 the Company anticipates that its operating leases will be recognized on the balance sheet as a lease liability if certain criteria is met, with a corresponding right of use asset. In February 2018, the FASB issued ASU 2018-02, Income Statement—Reporting Comprehensive Income (Topic 220)—Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income. This update was issued to address the income tax accounting treatment of the stranded tax effects within other comprehensive income due to the prohibition of backward tracing due to an income tax rate change that was initially recorded in other comprehensive income. This issue came about from the enactment of the Tax Cuts and Jobs Act on December 22, 2017, which changed the Company’s income tax rate from 35% to 21%. The ASU changed current accounting whereby an entity may elect to reclassify the stranded tax effect from accumulated other comprehensive income to retained earnings. The ASU is effective for periods beginning after December 15, 2018, although early adoption is permitted. The Company does not anticipate that the adoption of this ASU will have a material impact on its consolidated financial statements. In June 2018, the FASB issued ASU No. 2018-07, Compensation — Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting. The new standard expands the scope of Topic 718 to include all share-based payment transactions for acquiring goods and services from nonemployees. ASU No. 2018-07 specifies that Topic 718 applies to all share-based payment transactions in which the grantor acquires goods and services to be used or consumed in its own operations by issuing share-based payment awards. ASU NO. 2018-07 also clarifies that Topic 718 does not apply to share-based payments used to effectively provide (1) financing to the issuer or (2) awards granted in conjunction with selling goods or services to customers as part of a contract accounted for under ASC 606. ASU No. 2018-07 will be effective for the Company beginning after December 15, 2019, with early adoption permitted, but no earlier than the Company’s adoption of ASC 606. The Company is currently assessing the potential impact of adopting this guidance on its consolidated financial statements. Recent Accounting Standards In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606). The new standard is based on the principle that revenue should be recognized to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. ASU 2014-09 became effective for the Company in the first quarter of 2018 and allowed for full retrospective or a modified retrospective adoption approach. The Company adopted this new standard in January 2018 and it did not have a material adjustment on its consolidated financial statements. In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows, which clarifies the classification of certain cash receipts and payments. The specific cash flow issues addressed by ASU 2016-15, with the objective of reducing the existing diversity in practice, are as follows: (1) Debt prepayment or debt extinguishment costs; (2) Settlement of zero-coupon debt instruments or other debt instruments with insignificant coupon interest rates; (3) Contingent consideration payments made after a business combination; (4) Proceeds from the settlement of insurance claims; (5) Proceeds from the settlement of corporate-owned life insurance policies; (6) Distributions received from equity method investees; (7) Beneficial interest in securitization transactions; and (8) Separately identifiable cash flows and application of the predominance in principle. ASU 2016-15 became effective for fiscal years beginning after December 15, 2017. The Company adopted this new standard in January 2018 and it did not have a material impact on its consolidated financial statements. In October 2016, the FASB issued ASU. 2016-16, Income Taxes (Topic 740): Intra-Entity Transfers of Assets Other than Inventory. This update requires entities to recognize the income tax consequences of an intra-entity transfer of an asset other than inventory when the transfer occurs. This update is effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. Early adoption is permitted as of the beginning of a fiscal year. The new standard must be adopted using a modified retrospective transition method, which is a cumulative-effective adjustment to retained earnings as of the beginning of the first effective reporting period. The Company adopted this new standard in January 2018 and it did not have a material impact on its consolidated financial statements. In May 2017, the FASB issued ASU 2017-09, Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting, which provides guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. This update is effective for annual reporting periods beginning after December 15, 2017. Early adoption is permitted. The Company adopted this ASU in January 2018 and it did not have a material impact on its consolidated financial statements.

XML 18 R8.htm IDEA: XBRL DOCUMENT

Loss per Share

6 Months Ended

Jun. 30, 2018

Earnings Per Share [Abstract]

Loss per Share

(3) Loss per Share

Basic net loss per ordinary share is calculated by dividing net loss allocated to ordinary shareholders by the weighted average number of ordinary shares outstanding during the reporting period, excluding unvested restricted stock awards. Diluted net loss allocated to ordinary shareholders per share is calculated based on the weighted average number of Ordinary Shares and dilutive potential Ordinary Shares outstanding during the period. Dilutive potential ordinary shares consist of the shares issuable upon the exercise of options and upon the vesting of restricted shares under the treasury stock method. In net loss periods, basic and diluted net loss per share are identical since the effect of potential ordinary shares is anti-dilutive and therefore excluded.

Basic and diluted loss per share for the three and six months ended June 30, 2018 and 2017 were calculated as follows:

	Three-Months Ended June 30,						Six-Months Ended June 30,
	2018			2017			2018			2017
Net Loss	$	(2,251	)	$	(4,533	)	$	(4,265	)	$	(9,125	)
Weighted average shares outstanding - basic and diluted		17,079,548			16,956,056			17,042,358			15,618,001
Net loss per ordinary share - basic and diluted	$	(0.13	)	$	(0.27	)	$	(0.25	)	$	(0.58	)

XML 19 R9.htm IDEA: XBRL DOCUMENT

Equity Based Awards

6 Months Ended

Jun. 30, 2018

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Equity Based Awards

(4) Equity Based Awards

Equity Issued by Presbia PLC

Presbia Incentive Plan

	Three-Months Ended June 30,					Six-Months Ended June 30,
	2018			2017		2018			2017
Research and development	$	(49	)	$	126	$	(227	)	$	242
General and administrative		174			311		175			641
Sales and marketing		30			78		60			155
	$	155		$	515	$	8		$	1,038

Options

The following table sets forth the Company’s option activity for the six months ended June 30, 2018:

	Number of Presbia PLC Shares			Weighted Average Exercise Price Per Share		Aggregate Intrinsic Value
Balance, January 1, 2018		849,100		$	9.77		—
Granted		365,000		$	2.38		—
Exercised		—			—		—
Forfeited/cancelled/expired		(71,450	)	$	9.38		—
Balance, June 30, 2018		1,142,650		$	7.44		—
Vested, June 30, 2018		726,150		$	9.82		—
Non Vested, June 30, 2018		416,500		$	3.27		—
Exercisable, June 30, 2018		726,150		$	9.82		—

Employee Options

Non-Employee Options

	Three-Months Ended June 30,				Six-Months Ended June 30,
	2018		2017			2018		2017
Stock price per share	$0.85 - $1.13		$1.25 - $1.63			$0.85 - $1.95		$1.25 - $2.51
Expected term	6.6 - 7.1 Yrs.		7.7 - 8.4 Yrs			6.6 - 7.4 Yrs.		7.7 - 8.6 Yrs
Volatility	72.9% - 77.3%		79.1% - 83.5%			72.9% - 77.3%		79.1% - 90.0%
Dividends		—		—			—		—
Risk-free rate	2.8%		2.2%			2.6% - 2.8%		2.2% - 2.3%

Restricted Shares

The following table sets forth the Company’s restricted share activity for the three and six months ended June 30, 2018:

	Unvested Number of Shares			Weighted Average Fair Value per Share
Balance, December 31, 2017		134,367		$	3.78
Granted		23,255			2.15
Vested		(104,731	)		3.02
Forfeited/cancelled		—			—
Unvested, June 30, 2018		52,891		$	5.45

Restricted Share Units

The following table sets forth the Company’s RSU activity for the six months ended June 30, 2018:

	Unvested Number of Shares			Weighted Average Fair Value per Share
Balance, December 31, 2017		739,000		$	2.09
Granted		—			—
Vested		—			—
Forfeited/cancelled		(226,000	)		2.44
Unvested, June 30, 2018		513,000		$	1.32

Unrecognized Share-based Compensation

XML 20 R10.htm IDEA: XBRL DOCUMENT

Concentration of Credit Risk	6 Months Ended
Concentration of Credit Risk	Jun. 30, 2018
Risks And Uncertainties [Abstract]
Concentration of Credit Risk	(5) Concentration of Credit Risk The Company had cash of $3.3 million and $3.2 million as of June 30, 2018 and December 31, 2017, respectively, which consists of checking account deposits. The Company maintains cash balances at financial institutions located in the United States and secured by the Federal Deposit Insurance Corporation up to $250,000. As of June 30, 2018, the Company was not authorized to manufacture or sell any of its products or services within the United States and, as a result, all of the Company’ revenues are derived from foreign customers. With respect to suppliers for the microlens, the Company had a five-year supplier agreement that expired in January 2017 with a lens manufacturer in Israel from which the Company received 100% of its lens supply for use in commercial activities outside the United States. The Company also has its own manufacturing facility in Irvine, California that the Company believes will be sufficient to supply lenses for commercial activities outside the United States once existing inventory is utilized, as well as in the United States, pending FDA approval.

XML 21 R11.htm IDEA: XBRL DOCUMENT

Income Taxes

6 Months Ended

Jun. 30, 2018

Income Tax Disclosure [Abstract]

Income Taxes

(6) Income Taxes

A reconciliation of gross unrecognized tax benefits is as follows:



		June 30, 2018		December 31, 2017
Balance at the beginning of the year		199,000		—
Increases related to current year tax positions		75,000		199,000
Balance at the end of the year	$	274,000	$	199,000

XML 22 R12.htm IDEA: XBRL DOCUMENT

Equity Transaction with Related Party	6 Months Ended
Equity Transaction with Related Party	Jun. 30, 2018
Class Of Stock Disclosures [Abstract]
Equity Transaction with Related Party	(7) Equity Transaction with Related Party Private Placement with Related Party On April 12, 2018, Presbia PLC, its wholly-owned subsidiary, Presbia USA, Inc. and Richard Ressler, a member of Presbia PLC’s board of directors and its majority stockholder, entered into a Stock Purchase Agreement pursuant to which Mr. Ressler purchased in a private placement offering 100 preferred shares of the Company, with the rights set forth in the Subscription Letter, dated April 12, 2018, and 4,900 shares of preferred stock of Presbia USA for an aggregate purchase price of $5.0 million. Upon closing the offering, Mr. Ressler received a warrant to purchase 1,953,125 ordinary shares of Presbia PLC at an exercise price of $2.56 per share, subject to adjustments as provided under the terms of the warrants. The warrant is exercisable for five years from the issuance date and it contains a cashless exercise provision. The preferred shares of Presbia PLC and Presbia USA carry a one times liquidation preference. The preferred shares are redeemable upon a liquidation event in which all classes of equity holders are entitled to receive the same form of consideration and are redeemable at any time at our sole election, provided that a majority of the independent directors approve such redemption. The preferred shares accrue a dividend at the rate of 10% per annum during the first 18 months, 20% for months 19 through 24 and 30% from month 25 until such preferred shares are redeemed, payable in preferred shares on a quarterly basis. Undeclared dividends for the period from the date of issuance of April 12, 2018 to June 30, 2018 is 50,334 preferred shares of the Company. As long as the preferred shares remain outstanding, neither the Company nor its subsidiary shall take the following actions, without obtaining the prior consent of the holder of the preferred shares: (a) effect any alteration, repeal, change or amendment of the rights, privileges or preferences of the preferred shares in a manner that adversely affects the rights, privileges or preferences of those shares or any series thereof; (b) amend, modify or repeal any provision of the organizational documents in a manner that adversely affects the powers, preferences or rights of the preferred shares; (c) agree to any debt financing in an amount in excess of $8,000,000 (such amount being the maximum amount payable by the company under the debt instruments); (d) execute a guarantee; (e) effect any restructuring or liquidation; (f) settle any lawsuit or civil investigation requiring the payment of more than $1,000,000; or (g) execute any document or enter into any arrangement that has a potential liability to the Company in excess of $1,000,000. In addition, Presbia PLC guaranteed Presbia USA’s payment of the redemption price and any accrued and unpaid dividends with respect to the preferred shares issued by Presbia USA.

XML 23 R13.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies	6 Months Ended
Commitments and Contingencies	Jun. 30, 2018
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	(8) Commitments and Contingencies In May 2012, the Company entered into a five-year non-cancelable lease for office and manufacturing space in Irvine, California that was renewed on June 1, 2016 and provided for an extension of five consecutive years starting from the original lease expiration date of May 31, 2017 through May 31, 2022. The Company maintains a one-year lease (which is now month to month) in Dublin, Ireland that commenced on December 1, 2013. In February 2018, it terminated a 30-month lease in Amsterdam, the Netherlands, that commenced on January 1, 2016. This termination was based on a mutual agreement with the landlord. In December 2017, the Company vacated one of its Irvine, California locations and consolidated its operations into another location in Irvine. At December 31, 2017, a liability of $222,000, representing the fair value of the remaining lease obligation over the remaining 33 months was recorded as part of the short-term portion of deferred rent in the Consolidated Balance Sheet. During the six-month period ended June 30, 2018, the Company sublet the facility and settled the remaining lease obligation. Aggregate rent expense for the three months ended June 30, 2018 and 2017 was $113,000 and $168,000, respectively, and for the six months ended for the same period was $208,000 and $337,000, respectively. From time to time, the Company may be subject to legal proceedings and claims arising in the ordinary course of business. Management does not believe that the outcome of any of these matters will have a material effect on the Company’s consolidated financial operations.

XML 24 R14.htm IDEA: XBRL DOCUMENT

Subsequent Event	6 Months Ended
Subsequent Event	Jun. 30, 2018
Subsequent Events [Abstract]
Subsequent Event	(9) Subsequent Event None

XML 25 R15.htm IDEA: XBRL DOCUMENT

Basis of Presentation (Policies)	6 Months Ended
Basis of Presentation (Policies)	Jun. 30, 2018
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation. The accompanying consolidated financial statements have been derived from the historical cost basis of the assets and liabilities, financial condition and cash flows of Presbia PLC and Presbia Ireland, Limited, both organized in Ireland, Presbia Investments, a wholly-owned subsidiary of Presbia PLC organized in the Cayman Islands, and Presbia Ireland, Limited’s subsidiaries, Presbia Deutchland GmbH, Presbia USA, Inc., and OPL, LLC. Presbia Deutchland GmbH is organized in Germany, and Presbia USA, Inc. and OPL, LLC are both entities organized in the United States, and include Presbia USA, Inc.’s subsidiaries, Visitome, Inc. and PresbiBio, LLC, both organized in the United States, and OPL, LLC’s direct and indirect subsidiaries, PIP Holdings, C.V and Presbia Cooperatief U.A., both organized in the Netherlands, and PresbiOptical LLC, organized in the United States (collectively, including Presbia PLC, the “Company”). The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). The Company’s fiscal year ends on December 31. The entities presented in the consolidated financial statements have been under common control during the periods presented. All intercompany accounts have been eliminated in consolidation.
Basis of Presentation	Basis of Presentation. The accompanying unaudited consolidated financial statements as of June 30, 2018 and for the three and six months ended June 30, 2018 and 2017, respectively, have been prepared in accordance with United States generally accepted accounting principles (“U.S.GAAP”) for interim financial reporting, and with the instructions to Form 10-Q and Article 8 of Regulation S-X. The accompanying consolidated balance sheet at December 31, 2017 has been derived from the audited consolidated balance sheet at December 31, 2017, contained in the annual report on Form 10-K for the year ended December 31, 2017. These consolidated financial statements should be read in conjunction with the audited consolidated financial statements presented in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2017, filed with the Securities and Exchange Commission on March 30, 2018. In the opinion of management, the accompanying consolidated financial statements reflect all adjustments which are necessary for a fair presentation of the results of operations and cash flows for the periods presented. The results of operations for such interim periods are not necessarily indicative of results of operations to be expected for the full year. References to amounts in the consolidated financial statement sections are in thousands, except per share data, unless otherwise specified.
Liquidity	Liquidity At June 30, 2018, the Company has an accumulated deficit of $92.6 million and it expects to incur significant additional future operating losses. As it continues to incur losses, the Company’s transition to profitability will depend on the successful development, approval and commercialization of its microlens. The Company may never achieve profitability, and unless and until it does, it will need to continue to raise additional capital. Based on the Company’s current business plan, management believes that its cash and cash equivalents at June 30, 2018 will not be sufficient to meet its anticipated cash requirements during the twelve-month period subsequent to the issuance of the financial statements included in this Quarterly Report on Form 10-Q. These factors raise substantial doubt about the Company’s ability to continue as a going concern within one year from the date this Quarterly Report on Form 10-Q is filed with the U.S. Securities and Exchange Commission (SEC). The Company’s current commercialization strategy is targeted to countries where the Company can establish the market for its technology. This commercialization strategy will undergo continual prioritization and in the future the Company may adjust its commercialization efforts to preserve its existing cash or realize better results than anticipated which could have a positive impact on cash. The Company’s U.S. pivotal clinical trial and planned FDA approval is its highest priority. The Company must raise additional capital to fund its operations. It plans to raise additional capital through equity offerings, debt financings, collaborations and/or licensing arrangements. Additional funds may not be available when the Company needs them on terms that are acceptable to the Company, or at all. If adequate funds are not available on acceptable terms, the Company may be required to delay, reduce the scope of, or curtail, its operations. To the extent that the Company raises additional funds by issuing equity securities, its shareholders will experience dilution, and debt financing, if available, may involve restrictive covenants.
Revenue Recognition	Revenue Recognition Prior to 2018, we recognized revenue when there is persuasive evidence that an arrangement exists with our customers, selling prices are fixed or determinable, title or risk of loss has passed, and collection is reasonably assured. Revenue was recognized upon shipment and payments are either received in advance, or net 30 days for lenses or net 14 days for accessories. Distributor arrangements included certain perfunctory acceptance provisions and a one-year warranty, from the date of shipment, that products are free from defects in material workmanship. Under such provisions customers may reject shipments via written notifications ranging from 14-45 days or exchange defective product under warranty for the same non-defective product. We have not had any significant rejected shipments or warranty claims. We did not grant price concessions to our distributors. In 2012, we changed our commercialization strategy from exclusively using distributors to also targeting refractive laser centers equipped with femtosecond lasers, except in countries that require the use of distributors or sales representatives. In December 2017, in light our re-ordering of operational priorities, we have focused our commercialization and clinical trial efforts outside of the U.S. in Germany and South Korea, including established ophthalmic clinics in those countries. We recognize revenue from laser centers and ophthalmic clinics based upon an analysis of the terms of each customer arrangement and upon determination that persuasive evidence of an arrangement exists, selling prices are fixed or determinable, title or risk of loss has passed, and collection is reasonably assured. Revenues from laser centers and ophthalmic clinics during the three and six months ended June 30, 2018 and 2017 were not material. Effective January 1, 2018, the Company adopted the provisions of Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 606, Revenue from Contracts with Customers (“ASC 606”), using the modified retrospective transition method. Under this method, the Company recognizes revenue based on an analysis of the goods and services provided to our customers in the ordinary course. We analyze all commercial agreements to identify (i) contracts and arrangements with customers that meet the criteria for revenue recognition under the new standard (ii) identify all performance obligations under the contractual arrangement, such as the delivery of our Microlens to our customers and any other deliverable(s) as defined in a commercial arrangement (iii) the determination of the transaction price and the allocation of such pricing over the defined contractual obligations in the contract with the customer and (iv) the recognition of revenue once the customer has assumed control over the contractual obligations. Control refers to the ability on the part of the customer to obtain substantially all the benefits of possession of the delivered product or service.
Foreign Currency	Foreign Currency The functional currency of subsidiaries outside the United States of America is the U.S. Dollar. Transactions in foreign currencies during the year are re-measured at rates of exchange on the dates of the transactions. Gains and losses related to re-measurement of items arising through operating activities are accounted for in the statement of operations and comprehensive loss and included in general and administrative expense. Aggregate foreign exchange gains and losses are included in the Condensed Consolidated Statement of Operations. Aggregate foreign exchange gain was $28,000 for the three months ended June 30, 2018, and aggregate foreign exchange loss was $24,000 for the six months ended June 30, 2018. Aggregate foreign exchange loss was $52,000 and $79,000 for the three and six months ended June 30, 2017, respectively.
Comprehensive Loss	Comprehensive Loss Comprehensive income or loss is defined as a change in equity of a company attributable to all transactions excluding those transactions resulting from investment with owners and distributions to owners. There were no differences between net loss and comprehensive loss in the three and six months ended June 30, 2018 and 2017.
Future Accounting Pronouncements	Future Accounting Pronouncements In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). The new standard requires lessees to recognize most leases on their balance sheets as lease liabilities with corresponding right-of-use assets and eliminates certain real estate-specific provisions. ASU 2016-02 will be effective for the Company in the first quarter of 2019. ASU 2016-02 will be adopted on a modified retrospective transition basis for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements. Although the Company is currently evaluating the full impact of ASU 2016-02 on its consolidated financial statements, upon adoption of ASU 2016-02 the Company anticipates that its operating leases will be recognized on the balance sheet as a lease liability if certain criteria is met, with a corresponding right of use asset. In February 2018, the FASB issued ASU 2018-02, Income Statement—Reporting Comprehensive Income (Topic 220)—Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income. This update was issued to address the income tax accounting treatment of the stranded tax effects within other comprehensive income due to the prohibition of backward tracing due to an income tax rate change that was initially recorded in other comprehensive income. This issue came about from the enactment of the Tax Cuts and Jobs Act on December 22, 2017, which changed the Company’s income tax rate from 35% to 21%. The ASU changed current accounting whereby an entity may elect to reclassify the stranded tax effect from accumulated other comprehensive income to retained earnings. The ASU is effective for periods beginning after December 15, 2018, although early adoption is permitted. The Company does not anticipate that the adoption of this ASU will have a material impact on its consolidated financial statements. In June 2018, the FASB issued ASU No. 2018-07, Compensation — Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting. The new standard expands the scope of Topic 718 to include all share-based payment transactions for acquiring goods and services from nonemployees. ASU No. 2018-07 specifies that Topic 718 applies to all share-based payment transactions in which the grantor acquires goods and services to be used or consumed in its own operations by issuing share-based payment awards. ASU NO. 2018-07 also clarifies that Topic 718 does not apply to share-based payments used to effectively provide (1) financing to the issuer or (2) awards granted in conjunction with selling goods or services to customers as part of a contract accounted for under ASC 606. ASU No. 2018-07 will be effective for the Company beginning after December 15, 2019, with early adoption permitted, but no earlier than the Company’s adoption of ASC 606. The Company is currently assessing the potential impact of adopting this guidance on its consolidated financial statements.
Recent Accounting Standards	Recent Accounting Standards In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606). The new standard is based on the principle that revenue should be recognized to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. ASU 2014-09 became effective for the Company in the first quarter of 2018 and allowed for full retrospective or a modified retrospective adoption approach. The Company adopted this new standard in January 2018 and it did not have a material adjustment on its consolidated financial statements. In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows, which clarifies the classification of certain cash receipts and payments. The specific cash flow issues addressed by ASU 2016-15, with the objective of reducing the existing diversity in practice, are as follows: (1) Debt prepayment or debt extinguishment costs; (2) Settlement of zero-coupon debt instruments or other debt instruments with insignificant coupon interest rates; (3) Contingent consideration payments made after a business combination; (4) Proceeds from the settlement of insurance claims; (5) Proceeds from the settlement of corporate-owned life insurance policies; (6) Distributions received from equity method investees; (7) Beneficial interest in securitization transactions; and (8) Separately identifiable cash flows and application of the predominance in principle. ASU 2016-15 became effective for fiscal years beginning after December 15, 2017. The Company adopted this new standard in January 2018 and it did not have a material impact on its consolidated financial statements. In October 2016, the FASB issued ASU. 2016-16, Income Taxes (Topic 740): Intra-Entity Transfers of Assets Other than Inventory. This update requires entities to recognize the income tax consequences of an intra-entity transfer of an asset other than inventory when the transfer occurs. This update is effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. Early adoption is permitted as of the beginning of a fiscal year. The new standard must be adopted using a modified retrospective transition method, which is a cumulative-effective adjustment to retained earnings as of the beginning of the first effective reporting period. The Company adopted this new standard in January 2018 and it did not have a material impact on its consolidated financial statements. In May 2017, the FASB issued ASU 2017-09, Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting, which provides guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. This update is effective for annual reporting periods beginning after December 15, 2017. Early adoption is permitted. The Company adopted this ASU in January 2018 and it did not have a material impact on its consolidated financial statements.

XML 26 R16.htm IDEA: XBRL DOCUMENT

Loss per Share (Tables)

6 Months Ended

Jun. 30, 2018

Earnings Per Share [Abstract]

Schedule of Calculation of Basic and Diluted Loss per Share

Basic and diluted loss per share for the three and six months ended June 30, 2018 and 2017 were calculated as follows:

	Three-Months Ended June 30,						Six-Months Ended June 30,
	2018			2017			2018			2017
Net Loss	$	(2,251	)	$	(4,533	)	$	(4,265	)	$	(9,125	)
Weighted average shares outstanding - basic and diluted		17,079,548			16,956,056			17,042,358			15,618,001
Net loss per ordinary share - basic and diluted	$	(0.13	)	$	(0.27	)	$	(0.25	)	$	(0.58	)

XML 27 R17.htm IDEA: XBRL DOCUMENT

Equity Based Awards (Tables)

6 Months Ended

Jun. 30, 2018

Share-Based Compensation Expense Included in Consolidated Statements of Operations

	Three-Months Ended June 30,					Six-Months Ended June 30,
	2018			2017		2018			2017
Research and development	$	(49	)	$	126	$	(227	)	$	242
General and administrative		174			311		175			641
Sales and marketing		30			78		60			155
	$	155		$	515	$	8		$	1,038

Schedule of Option Activity

The following table sets forth the Company’s option activity for the six months ended June 30, 2018:

	Number of Presbia PLC Shares			Weighted Average Exercise Price Per Share		Aggregate Intrinsic Value
Balance, January 1, 2018		849,100		$	9.77		—
Granted		365,000		$	2.38		—
Exercised		—			—		—
Forfeited/cancelled/expired		(71,450	)	$	9.38		—
Balance, June 30, 2018		1,142,650		$	7.44		—
Vested, June 30, 2018		726,150		$	9.82		—
Non Vested, June 30, 2018		416,500		$	3.27		—
Exercisable, June 30, 2018		726,150		$	9.82		—

Schedule of Restricted Shares Activity

The following table sets forth the Company’s restricted share activity for the three and six months ended June 30, 2018:

	Unvested Number of Shares			Weighted Average Fair Value per Share
Balance, December 31, 2017		134,367		$	3.78
Granted		23,255			2.15
Vested		(104,731	)		3.02
Forfeited/cancelled		—			—
Unvested, June 30, 2018		52,891		$	5.45

Schedule of RSU Activity

The following table sets forth the Company’s RSU activity for the six months ended June 30, 2018:

	Unvested Number of Shares			Weighted Average Fair Value per Share
Balance, December 31, 2017		739,000		$	2.09
Granted		—			—
Vested		—			—
Forfeited/cancelled		(226,000	)		2.44
Unvested, June 30, 2018		513,000		$	1.32

Non-employee options [Member]

Schedule of Black-Scholes Valuation Model Assumptions for Estimating the Fair Value of Share-Based Compensation

	Three-Months Ended June 30,				Six-Months Ended June 30,
	2018		2017			2018		2017
Stock price per share	$0.85 - $1.13		$1.25 - $1.63			$0.85 - $1.95		$1.25 - $2.51
Expected term	6.6 - 7.1 Yrs.		7.7 - 8.4 Yrs			6.6 - 7.4 Yrs.		7.7 - 8.6 Yrs
Volatility	72.9% - 77.3%		79.1% - 83.5%			72.9% - 77.3%		79.1% - 90.0%
Dividends		—		—			—		—
Risk-free rate	2.8%		2.2%			2.6% - 2.8%		2.2% - 2.3%

XML 28 R18.htm IDEA: XBRL DOCUMENT

Income Taxes (Tables)

6 Months Ended

Jun. 30, 2018

Income Tax Disclosure [Abstract]

Schedule of Reconciliation of Gross Unrecognized Tax Benefits

A reconciliation of gross unrecognized tax benefits is as follows:



		June 30, 2018		December 31, 2017
Balance at the beginning of the year		199,000		—
Increases related to current year tax positions		75,000		199,000
Balance at the end of the year	$	274,000	$	199,000

XML 29 R19.htm IDEA: XBRL DOCUMENT

Basis of Presentation - Additional Information (Detail) - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Accumulated deficit	$ 92,567	$ 88,302

XML 30 R20.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2017
Significant Accounting Policies [Line Items]
Warranty period, from the date of shipment			1 year
Income tax rate			21.00%		35.00%
General and Administrative Expense [Member]
Significant Accounting Policies [Line Items]
Aggregate foreign exchange gain (loss)	$ 28,000	$ (52,000)	$ (24,000)	$ (79,000)
Minimum [Member]
Significant Accounting Policies [Line Items]
Written notification period to reject shipments by customers			14 days
Maximum [Member]
Significant Accounting Policies [Line Items]
Written notification period to reject shipments by customers			45 days
Lenses [Member]
Significant Accounting Policies [Line Items]
Payments collection period			30 days
Accessories [Member]
Significant Accounting Policies [Line Items]
Payments collection period			14 days

XML 31 R21.htm IDEA: XBRL DOCUMENT

Loss per Share - Schedule of Calculation of Basic and Diluted Loss per Share (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Basic and diluted net loss per share
Net Loss	$ (2,251)	$ (4,533)	$ (4,265)	$ (9,125)
Weighted average shares outstanding - basic and diluted	17,079,548	16,956,056	17,042,358	15,618,001
Net loss per ordinary share - basic and diluted	$ (0.13)	$ (0.27)	$ (0.25)	$ (0.58)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

XML 32 R22.htm IDEA: XBRL DOCUMENT

Loss per Share - Additional Information (Detail) - shares	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Earnings Per Share [Abstract]
Antidilutive securities, not included in diluted net loss per calculation	1,049,795	1,152,500	972,019	1,050,000

XML 33 R23.htm IDEA: XBRL DOCUMENT

Equity Based Awards - Additional Information (Detail) - USD ($)		3 Months Ended		6 Months Ended
	Jan. 14, 2015	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock based compensation charge reversal		$ 86,000		$ 524,000
Options granted				365,000
Non-employee consultants and medical advisors [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Options granted		0	0	0	0
Employee Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Awards vesting period		5 years		5 years
Award expiration period		6 years 9 months		6 years 9 months
Options granted		365,000	0	0	0
Medical Advisory Board Compensation [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock awarded for services				23,255
Closing price per share		$ 2.15		$ 2.15
Restricted Share Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Award expiration period				7 years
Authorized issuance percentage of each recipient’s total RSU award				20.00%
Consecutive trading days				20 days
Wait or service period				1 year
Unrecognized compensation expense, weighted average period of recognition				10 months 24 days	2 years 4 months 24 days
Unrecognized compensation expense related to restricted shares/RSUs		$ 513,000	$ 7,710,000	$ 513,000	$ 7,710,000
Restricted shares [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Unrecognized compensation expense, weighted average period of recognition				1 year 9 months 18 days	1 year 6 months
Unrecognized compensation expense related to restricted shares/RSUs		226,000	290,000	$ 226,000	$ 290,000
Employee and non-employee options [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Unrecognized compensation expense related to options		$ 785,000	$ 2,740,000	$ 785,000	$ 2,740,000
Unrecognized compensation expense, weighted average period of recognition				2 years 3 months 18 days	1 year 8 months 12 days
Over five year period [Member] \| Employee Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Generally vesting percentage for annual		20.00%		20.00%
Threshold Price Period 1 [Member] \| Restricted Share Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share price threshold				$ 10.00
Threshold Price Period 2 [Member] \| Restricted Share Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share price threshold				15.00
Threshold Price Period 3 [Member] \| Restricted Share Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share price threshold				20.00
Threshold Price Period 4 [Member] \| Restricted Share Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share price threshold				25.00
Threshold Price Period 5 [Member] \| Restricted Share Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share price threshold				$ 30.00
Presbia Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Awards vesting period	5 years
Ordinary shares authorized for issuance	2,200,000
Ordinary shares available for future grants and awards		367,591		367,591
Award expiration period	10 years
Award expiration date				Jan. 14, 2025
Presbia Incentive Plan [Member] \| Over five year period [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Generally vesting percentage for annual	20.00%

XML 34 R24.htm IDEA: XBRL DOCUMENT

Equity Based Awards - Share-Based Compensation Expense Included in Consolidated Statements of Operations (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Share-based compensation expense	$ 155	$ 515	$ 8	$ 1,038
Research and development [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Share-based compensation expense	(49)	126	(227)	242
General and administrative [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Share-based compensation expense	174	311	175	641
Sales and marketing [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Share-based compensation expense	$ 30	$ 78	$ 60	$ 155

XML 35 R25.htm IDEA: XBRL DOCUMENT

Equity Based Awards - Schedule of Option Activity (Detail) - $ / shares	6 Months Ended
	Jun. 30, 2018
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Number of Presbia PLC Shares, Beginning Balance	849,100
Number of shares, Granted	365,000
Number of Presbia PLC Shares, Forfeited/cancelled/expired	(71,450)
Number of Presbia PLC Shares, Ending Balance	1,142,650
Number of Presbia PLC Shares, Vested	726,150
Number of Presbia PLC Shares, Non Vested	416,500
Number of Presbia PLC Shares, Exercisable	726,150
Weighted Average Exercise Price Per Share, Beginning Balance	$ 9.77
Weighted Average Exercise Price Per Share, Granted	2.38
Weighted Average Exercise Price Per Share, Forfeited/cancelled/expired	9.38
Weighted Average Exercise Price Per Share, Ending Balance	7.44
Weighted Average Exercise Price Per Share, Vested	9.82
Weighted Average Exercise Price Per Share, Non Vested	3.27
Weighted Average Exercise Price Per Share, Exercisable	$ 9.82

XML 36 R26.htm IDEA: XBRL DOCUMENT

Equity Based Awards - Schedule of Black-Scholes Valuation Model Assumptions for Estimating the Fair Value of Share-Based Compensation (Detail) - Non-employee options [Member] - $ / shares	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Volatility minimum	72.90%	79.10%	72.90%	79.10%
Volatility maximum	77.30%	83.50%	77.30%	90.00%
Risk-free rate	2.80%	2.20%
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock price per share	$ 0.85	$ 1.25	$ 0.85	$ 1.25
Expected term	6 years 7 months 6 days	7 years 8 months 12 days	6 years 7 months 6 days	7 years 8 months 12 days
Risk-free rate			2.60%	2.20%
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock price per share	$ 1.13	$ 1.63	$ 1.95	$ 2.51
Expected term	7 years 1 month 6 days	8 years 4 months 24 days	7 years 4 months 24 days	8 years 7 months 6 days
Risk-free rate			2.80%	2.30%

XML 37 R27.htm IDEA: XBRL DOCUMENT

Equity Based Awards - Schedule of Restricted Share Activity (Detail) - Restricted shares [Member]	6 Months Ended
	Jun. 30, 2018 $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Unvested Number of Shares, Beginning Balance \| shares	134,367
Unvested Number of Shares, Granted \| shares	23,255
Unvested Number of Shares, Vested \| shares	(104,731)
Unvested Number of Shares, Ending Balance \| shares	52,891
Weighted Average Fair Value per Share, Beginning Balance \| $ / shares	$ 3.78
Weighted Average Fair Value per Share, Granted \| $ / shares	2.15
Weighted Average Fair Value per Share, Vested \| $ / shares	3.02
Weighted Average Fair Value per Share, Ending Balance \| $ / shares	$ 5.45

XML 38 R28.htm IDEA: XBRL DOCUMENT

Equity Based Awards - Schedule of RSU Activity (Detail) - Restricted Share Units [Member]	6 Months Ended
	Jun. 30, 2018 $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Unvested Number of Shares, Beginning Balance \| shares	739,000
Unvested Number of Shares, Forfeited/cancelled \| shares	(226,000)
Unvested Number of Shares, Ending Balance \| shares	513,000
Weighted Average Fair Value per Share, Beginning Balance \| $ / shares	$ 2.09
Weighted Average Fair Value per Share, Forfeited/cancelled \| $ / shares	2.44
Weighted Average Fair Value per Share, Ending Balance \| $ / shares	$ 1.32

XML 39 R29.htm IDEA: XBRL DOCUMENT

Concentration of Credit Risk - Additional Information (Detail) - USD ($)	6 Months Ended
	Jun. 30, 2018	Dec. 31, 2017	Jun. 30, 2017	Dec. 31, 2016
Concentration Risk [Line Items]
Cash	$ 3,328,000	$ 3,236,000	$ 10,668,000	$ 7,333,000
Supplier agreement term	5 years
Supplier agreement, expiration date	2017-01
Cost of Goods, Total [Member] \| Supplier Concentration Risk [Member]
Concentration Risk [Line Items]
Concentration risk percentage	100.00%
Federal Deposit Insurance Corporation [Member] \| Maximum [Member]
Concentration Risk [Line Items]
Cash	$ 250,000

XML 40 R30.htm IDEA: XBRL DOCUMENT

Income Taxes - Additional Information (Detail) - USD ($)	6 Months Ended
	Jun. 30, 2018	Dec. 31, 2017	Dec. 31, 2016
Income Tax [Line Items]
Description of uncertain income tax position being recognized	An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained.
Liability for unpaid irish income taxes	$ 274,000	$ 199,000	$ 0
Accrued interest and penalties	35,000	39,000
Foreign [Member] \| Ireland [Member]
Income Tax [Line Items]
Liability for unpaid irish income taxes	$ 274,000	$ 199,000

XML 41 R31.htm IDEA: XBRL DOCUMENT

Income Taxes - Schedule of Reconciliation of Gross Unrecognized Tax Benefits (Detail) - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2018	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Balance at the beginning of the year	$ 199,000	$ 0
Increases related to current year tax positions	75,000	199,000
Balance at the end of the year	$ 274,000	$ 199,000

XML 42 R32.htm IDEA: XBRL DOCUMENT

Equity Transaction with Related Party - Additional Information (Detail) - USD ($)		3 Months Ended	6 Months Ended
	Apr. 12, 2018	Jun. 30, 2018	Jun. 30, 2018
Related Party Transaction [Line Items]
Number of preferred shares with undeclared dividends		50,334
Preferred shares description			As long as the preferred shares remain outstanding, neither the Company nor its subsidiary shall take the following actions, without obtaining the prior consent of the holder of the preferred shares: (a) effect any alteration, repeal, change or amendment of the rights, privileges or preferences of the preferred shares in a manner that adversely affects the rights, privileges or preferences of those shares or any series thereof; (b) amend, modify or repeal any provision of the organizational documents in a manner that adversely affects the powers, preferences or rights of the preferred shares; (c) agree to any debt financing in an amount in excess of $8,000,000 (such amount being the maximum amount payable by the company under the debt instruments); (d) execute a guarantee; (e) effect any restructuring or liquidation; (f) settle any lawsuit or civil investigation requiring the payment of more than $1,000,000; or (g) execute any document or enter into any arrangement that has a potential liability to the Company in excess of $1,000,000.
Debt financing threshold	$ 8,000,000
Legal settlement threshold	1,000,000
Potential liability under arrangment threshold	$ 1,000,000
First 18 Months [Member]
Related Party Transaction [Line Items]
Preferred shares dividend rate	10.00%
19 through 24 Months [Member]
Related Party Transaction [Line Items]
Preferred shares dividend rate	20.00%
Month 25 and Thereafter [Member]
Related Party Transaction [Line Items]
Preferred shares dividend rate	30.00%
Richard Ressler [Member]
Related Party Transaction [Line Items]
Ordinary shares called by warrants	1,953,125
Exercise price	$ 2.56
Warrant exercisable period	5 years
Richard Ressler [Member] \| Preferred Shares [Member] \| Private Placement [Member]
Related Party Transaction [Line Items]
Preferred shares aggregate purchase price	$ 5,000,000
Richard Ressler [Member] \| Preferred Shares [Member] \| Private Placement [Member] \| Presbia PLC [Member]
Related Party Transaction [Line Items]
Preferred shares issued	100
Richard Ressler [Member] \| Preferred Shares [Member] \| Private Placement [Member] \| Presbia USA, Inc [Member]
Related Party Transaction [Line Items]
Preferred shares issued	4,900

XML 43 R33.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies - Additional Information (Detail)					1 Months Ended	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 01, 2016	Jan. 02, 2016	Dec. 01, 2013	May 31, 2012	Dec. 31, 2017 USD ($) Facility	Jun. 30, 2018 USD ($)	Jun. 30, 2017 USD ($)	Jun. 30, 2018 USD ($)	Jun. 30, 2017 USD ($)	Dec. 31, 2017 USD ($)
Commitments And Contingencies [Line Items]
Rent expense						$ 113,000	$ 168,000	$ 208,000	$ 337,000
California [Member]
Commitments And Contingencies [Line Items]
Lease period				5 years
Lease expiration period	May 31, 2022			May 31, 2017
Lease renewal term	5 years
Ireland [Member]
Commitments And Contingencies [Line Items]
Lease period			1 year
Lease renewal term			1 month
Lease commencement date			Dec. 01, 2013
The Netherlands [Member]
Commitments And Contingencies [Line Items]
Lease period		30 months
Lease commencement date		Jan. 01, 2016
Lease termination period		2018-02
Reorganization [Member] \| California [Member]
Commitments And Contingencies [Line Items]
Number of facilities vacated \| Facility					1
Fair value of remaining lease obligation					$ 222,000					$ 222,000
Vacated facility remaining lease term										33 months

EXCEL 44 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 46 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 48 FilingSummary.xml IDEA: XBRL DOCUMENT 3.10.0.1 html 103 188 1 false 39 0 false 6 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.presbia.com/20180630/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 100010 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.presbia.com/20180630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 100020 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://www.presbia.com/20180630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 100030 - Statement - Condensed Consolidated Statements of Operations (Unaudited) Sheet http://www.presbia.com/20180630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited Condensed Consolidated Statements of Operations (Unaudited) Statements 4 false false R5.htm 100040 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://www.presbia.com/20180630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 5 false false R6.htm 100050 - Disclosure - Basis of Presentation Sheet http://www.presbia.com/20180630/taxonomy/role/DisclosureBasisOfPresentation Basis of Presentation Notes 6 false false R7.htm 100060 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.presbia.com/20180630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 7 false false R8.htm 100070 - Disclosure - Loss per Share Sheet http://www.presbia.com/20180630/taxonomy/role/DisclosureLossPerShare Loss per Share Notes 8 false false R9.htm 100080 - Disclosure - Equity Based Awards Sheet http://www.presbia.com/20180630/taxonomy/role/DisclosureEquityBasedAwards Equity Based Awards Notes 9 false false R10.htm 100090 - Disclosure - Concentration of Credit Risk Sheet http://www.presbia.com/20180630/taxonomy/role/DisclosureConcentrationOfCreditRisk Concentration of Credit Risk Notes 10 false false R11.htm 100100 - Disclosure - Income Taxes Sheet http://www.presbia.com/20180630/taxonomy/role/DisclosureIncomeTaxes Income Taxes Notes 11 false false R12.htm 100110 - Disclosure - Equity Transaction with Related Party Sheet http://www.presbia.com/20180630/taxonomy/role/DisclosureEquityTransactionWithRelatedParty Equity Transaction with Related Party Notes 12 false false R13.htm 100120 - Disclosure - Commitments and Contingencies Sheet http://www.presbia.com/20180630/taxonomy/role/DisclosureCommitmentsAndContingencies Commitments and Contingencies Notes 13 false false R14.htm 100130 - Disclosure - Subsequent Event Sheet http://www.presbia.com/20180630/taxonomy/role/DisclosureSubsequentEvent Subsequent Event Notes 14 false false R15.htm 100140 - Disclosure - Basis of Presentation (Policies) Sheet http://www.presbia.com/20180630/taxonomy/role/DisclosureBasisOfPresentationPolicies Basis of Presentation (Policies) Policies http://www.presbia.com/20180630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies 15 false false R16.htm 100150 - Disclosure - Loss per Share (Tables) Sheet http://www.presbia.com/20180630/taxonomy/role/DisclosureLossPerShareTables Loss per Share (Tables) Tables http://www.presbia.com/20180630/taxonomy/role/DisclosureLossPerShare 16 false false R17.htm 100160 - Disclosure - Equity Based Awards (Tables) Sheet http://www.presbia.com/20180630/taxonomy/role/DisclosureEquityBasedAwardsTables Equity Based Awards (Tables) Tables http://www.presbia.com/20180630/taxonomy/role/DisclosureEquityBasedAwards 17 false false R18.htm 100170 - Disclosure - Income Taxes (Tables) Sheet http://www.presbia.com/20180630/taxonomy/role/DisclosureIncomeTaxesTables Income Taxes (Tables) Tables http://www.presbia.com/20180630/taxonomy/role/DisclosureIncomeTaxes 18 false false R19.htm 100180 - Disclosure - Basis of Presentation - Additional Information (Detail) Sheet http://www.presbia.com/20180630/taxonomy/role/DisclosureBasisOfPresentationAdditionalInformationDetail Basis of Presentation - Additional Information (Detail) Details 19 false false R20.htm 100190 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail) Sheet http://www.presbia.com/20180630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail Summary of Significant Accounting Policies - Additional Information (Detail) Details 20 false false R21.htm 100200 - Disclosure - Loss per Share - Schedule of Calculation of Basic and Diluted Loss per Share (Detail) Sheet http://www.presbia.com/20180630/taxonomy/role/DisclosureLossPerShareScheduleOfCalculationOfBasicAndDilutedLossPerShareDetail Loss per Share - Schedule of Calculation of Basic and Diluted Loss per Share (Detail) Details 21 false false R22.htm 100210 - Disclosure - Loss per Share - Additional Information (Detail) Sheet http://www.presbia.com/20180630/taxonomy/role/DisclosureLossPerShareAdditionalInformationDetail Loss per Share - Additional Information (Detail) Details 22 false false R23.htm 100220 - Disclosure - Equity Based Awards - Additional Information (Detail) Sheet http://www.presbia.com/20180630/taxonomy/role/DisclosureEquityBasedAwardsAdditionalInformationDetail Equity Based Awards - Additional Information (Detail) Details 23 false false R24.htm 100230 - Disclosure - Equity Based Awards - Share-Based Compensation Expense Included in Consolidated Statements of Operations (Detail) Sheet http://www.presbia.com/20180630/taxonomy/role/DisclosureEquityBasedAwardsShareBasedCompensationExpenseIncludedInConsolidatedStatementsOfOperationsDetail Equity Based Awards - Share-Based Compensation Expense Included in Consolidated Statements of Operations (Detail) Details 24 false false R25.htm 100240 - Disclosure - Equity Based Awards - Schedule of Option Activity (Detail) Sheet http://www.presbia.com/20180630/taxonomy/role/DisclosureEquityBasedAwardsScheduleOfOptionActivityDetail Equity Based Awards - Schedule of Option Activity (Detail) Details 25 false false R26.htm 100250 - Disclosure - Equity Based Awards - Schedule of Black-Scholes Valuation Model Assumptions for Estimating the Fair Value of Share-Based Compensation (Detail) Sheet http://www.presbia.com/20180630/taxonomy/role/DisclosureEquityBasedAwardsScheduleOfBlackScholesValuationModelAssumptionsForEstimatingFairValueOfShareBasedCompensationDetail Equity Based Awards - Schedule of Black-Scholes Valuation Model Assumptions for Estimating the Fair Value of Share-Based Compensation (Detail) Details 26 false false R27.htm 100260 - Disclosure - Equity Based Awards - Schedule of Restricted Share Activity (Detail) Sheet http://www.presbia.com/20180630/taxonomy/role/DisclosureEquityBasedAwardsScheduleOfRestrictedShareActivityDetail Equity Based Awards - Schedule of Restricted Share Activity (Detail) Details 27 false false R28.htm 100270 - Disclosure - Equity Based Awards - Schedule of RSU Activity (Detail) Sheet http://www.presbia.com/20180630/taxonomy/role/DisclosureEquityBasedAwardsScheduleOfRSUActivityDetail Equity Based Awards - Schedule of RSU Activity (Detail) Details 28 false false R29.htm 100280 - Disclosure - Concentration of Credit Risk - Additional Information (Detail) Sheet http://www.presbia.com/20180630/taxonomy/role/DisclosureConcentrationOfCreditRiskAdditionalInformationDetail Concentration of Credit Risk - Additional Information (Detail) Details 29 false false R30.htm 100290 - Disclosure - Income Taxes - Additional Information (Detail) Sheet http://www.presbia.com/20180630/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail Income Taxes - Additional Information (Detail) Details 30 false false R31.htm 100300 - Disclosure - Income Taxes - Schedule of Reconciliation of Gross Unrecognized Tax Benefits (Detail) Sheet http://www.presbia.com/20180630/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfGrossUnrecognizedTaxBenefitsDetail Income Taxes - Schedule of Reconciliation of Gross Unrecognized Tax Benefits (Detail) Details 31 false false R32.htm 100310 - Disclosure - Equity Transaction with Related Party - Additional Information (Detail) Sheet http://www.presbia.com/20180630/taxonomy/role/DisclosureEquityTransactionWithRelatedPartyAdditionalInformationDetail Equity Transaction with Related Party - Additional Information (Detail) Details 32 false false R33.htm 100320 - Disclosure - Commitments and Contingencies - Additional Information (Detail) Sheet http://www.presbia.com/20180630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail Commitments and Contingencies - Additional Information (Detail) Details 33 false false All Reports Book All Reports lens-20180630.xml lens-20180630.xsd lens-20180630_cal.xml lens-20180630_def.xml lens-20180630_lab.xml lens-20180630_pre.xml http://fasb.org/srt/2018-01-31 http://xbrl.sec.gov/dei/2018-01-31 http://fasb.org/us-gaap/2018-01-31 http://xbrl.sec.gov/stpr/2018-01-31 http://xbrl.sec.gov/country/2017-01-31 true true ZIP 50 0001564590-18-021287-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001564590-18-021287-xbrl.zip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end